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The Behaviour of Natural Killer Lymphocytes in Patients with Benign
and Malignant Disease Undergoing Surgery.
Summary.
The natural killer lymphocyte is of interest to both the cancer
researcher and cancer surgeon because of its likely role in immune
surveillance and defence against developing tumours and metastatic
spread of tumours.
In this study, the influence of established tumours of the stomach
and colon was studied with respect to the capacity of the natural
killer lymphocytes of the tumour bearing host to kill the K562 tumour
target cell line. Patients with localised malignant disease had
natural killer lymphocyte activity within the range of normal benign
controls, however those patients with advanced tumours and metastatic
spread, displayed grossly depressed levels of natural cytotoxicity. The
passage of NK lymphocytes through the tumour circulation did not
significantly alter NK cytotoxicity to K562 targets and NK lymphocyte
numbers as identified by the Leu 7 monoclonal antibody were not reduced
after passage through the tumour circulation. Plasma from the peripheral
venous blood of tumour bearing patients was found to inhibit the natural
killer lymphocyte activity of normal controls to kill K562 target cells;
this effect was observed to a much greater degree, however, when control
lymphocytes were exposed to plasma from venous blood draining the tumour
circulation. This strongly suggests the production of factors by the
tumour or tumour infiltrating host cells which inhibit the host natural
killer lymphocyte response to tumour cells.
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Surgical resection of a malignant tumour under general anaesthesia
remains the main hope of curing the disease therefore the behaviour
of natural killer lymphocytes in patients with cancer during
anaesthesia and surgical operation was studied. The cytotoxicity of
host natural killer lymphocytes to tumour target cells was enhanced
during surgery in those patients with localised malignant tumours and
benign controls, however patients with metastatic disease did not show
this phenomenon. The observed enhancement of natural cytotoxicity
occurred during the surgical procedure under general anaesthesia but
not during anaesthesia alone, and was found to be an interferon
independent phenomenon with the elevated cytotoxicity correlating well
with an absolute rise in the Leu 7 positive (NK) lymphocytes in the
circulating blood during surgery. Natural cytotoxicity to tumour target
cells was further enhanced in vitro by exposure of host lymphocytes to
human leucocyte a interferon. There may, therefore, be a place for
selective immunological enhancement of the host antitumour mechanisms
such as the natural killer lymphocyte system by agents such as interferon
in the perioperative period. Patients undergoing surgical resection of
a malignant tumour have large numbers of circulating malignant cells
which can implant to form metastases and stimulation of host defences
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Introduction.
A malignant tumour develops because of the uninhibited growth of
abnormal or transformed host cells which have escaped from the normal
homeostatic mechanisms which control cell growth and mobility. Cells
from malignant tumours have the capacity to multiply indefinitely
until they have outgrown their supply of nutrients or have been
destroyed by drugs, irradiation or surgical removal of the tumour mass.
Malignant cells from solid tumours do not possess the normal intercellular
adhesive properties which limit cell mobility and unlike cells from a
benign tumour, malignant cells are able to penetrate endothelial lined
surfaces and hence establish direct extensions of tumour in lymphatic
and vascular channels capable of releasing tumour cell emboli which after
implantation form distant tumour metastases in lymph nodes and organs
such as liver, lung and bone.
The breakdown of the normal cellular growth control mechanisms and the
response of the host to the developing tumour have been the subject of
intense scientific interest in both experimental tumours and those
arising in the human host. The study of animal tumour models which like
human malignant tumours metastasize spontaneously, will aid in the
understanding and future treatment of patients with cancer.
1.1 Cellular growth control mechanisms - immune surveillance.
A multicellular organism like man requires a mechanism to control
unhinhibited cell growth and eliminate cells that are faulty and may
ultimately harm the existence of the host. An early concept of such
a mechanism was that of allogenic inhibition conceived after
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Bergheden and Hellstrom (1966) reported that mouse tumour cells of
different histocompatibility types from the host failed to grow in
contact with these cells. Klein (1966) proposed that control of
cellular integrity in a multicellular organism was as likely to be
due to allogenic inhibition as a surveillance mechanism based on
immunological mechanisms, however the main evidence against this
proposal is that allophenic mice, namely mice with cells of 2
genetically different histocompatibility types with different cell
surface antigens can exist. (Mintz and Silvers,1965).
Thomas (1959) suggested that "it is a universal requirement of multi¬
cellular organisms to preserve uniformity of cell type ... the
phenomenon of homograft rejection will turn out to represent a primary
mechanism for natural defence against neoplasia". With the discovery
of new antigens in tumours arising in pure line mice (Foley 1953; Prehn
and Main 1957), Burnet (1970) conceived that it was possible that small
accumulations of tumour cells could develop but because of the tumour
specific antigens expressed by these cells, they would provoke an
effective immunological reaction with subsequent regression of the
tumour. This system of surveillance and tumour lysis is believed to
have arisen in vertebrate animals as a defence against early death from
tumours developing from cells with malignant potential. These particular
cells could arise as a result of aberrant division of a single cell with
the subsequent formation of a malignant clone of cells which would
multiply thus ultimately forming a tumour.
The most primitive vertebrate creature living today is the lamprey and
it has been studied to determine the origins of the immune system
present in higher vertebrate animals including man. The lamprey has a
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very poor antibody response with very low levels of circulating
immunoglobulin (0.2 mg/ml) which is homologous with lgFI. (Marchalonis
and Edelman 1968). It does however possess an active cell mediated
response to tuberculin and whilst skin autografts were accepted skin
homografts gave a classical rejection response (Finstad and Good 1966).
The lamprey does not possess a thymus, spleen or recognisable bone
marrow.but there are collections of lymphoid cells which may have a
function similar to these organs. The lamprey displays the most basic
requirements for an active cell mediated immunological surveillance
mechanism with:
1. Collections of lymphoid cells which are thought to be the functional
equivalent of the thymus, spleen and bone marrow of higher vertbrates.
2. Circulating lymphoid cells.
3. The capacity to reject tissue homografts.
4. The ability to develop a delayed hypersensitivity reaction to antigens.
Cancer and other malignant tumours appear to be almost exclusively the
fate of vertebrates since creatures of lower phylogenetic orders such as
insects very rarely develop tumours. A single cell line in a multicellular
organism such as man is thought to undergo a finite number of cell
divisions unlike a malignant cell line which can divide indefinitely.
In the average human lifespan there are lO"1^ cell divisions and therefore
the possibility of aberrant cell division producing cells with malignant
potential is great and the requirement for a mechanism to control and
eliminate abnormal cells is obvious.
There is clinical evidence in both animals and man for an active immune
surveillance mechanism which can recognise abnormal cells and destroy
them at a premalignant or frankly malignant stage. The commonly cited
evidence (Burnet 1970) for active immunological surveillance is as
follows:
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1. There is an increased incidence of malignant disease at the
extremes of life when immunological activity is low.
2. Depression of the thymus dependent immunological response system
is associated with an increased incidence of malignant disease.
(This has now been questioned with the discovery of natural
killer lymphocytes in nude mice which have no thymus and the lack
of tumour development in mice with normal levels of natural killer
cell activity).
3. Patients who are immunosuppressed (e.g. renal transplant recipients)
have a higher incidence of tumours, mainly lymphomas and skin cancers,
than normal controls.
4. In human autopsies, the chance finding of malignant tumours is far
higher than the expected incidence of these types of tumours during
life. This finding implies that tumour formation is reasonably
common but does not progress due to active restriction or lysis of
tumour by a functioning immune surveillance mechanism.
/
3. There exists documented cases of spontaneous regression of established
malignant tumours in human patients.
Everson and Cole (1966) extensively reviewed the literature of well
documented human tumours which had undergone spontaneous regression.
Reports such as these plus the clinical observation that many tumours
appear to lie dormant for months or even years would generally support
the concept of immune surveillance against malignant tumours arising in
the human host. Why this system is not effective in all malignant tumours
remains under intense investigation, the two most likley possibilities
being:
1. That the host fails to recognise the tumour as foreign tissue.
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2. That tumour recognition by the host does occur, but the host
response is abrogated by tumour products or tumour directed
suppression by host cells.
The establishment of a host response by the tumour is vital for tumour
directed cytotoxic mechanisms to be activated by the host.
1.2 Mechanism of the immune response to tumours.
Conventional immunological theory dictates that for an immune response
to be mounted by the host towards foreign or abnormal cells, whether
they be invading micro-organisms or developing tumour cells, the cells
must be recognised as 'non self' by the host with the detection of
novel antigens on the cell surface membrane. The evidence that human
tumours possess tumour specific antigens capable of stimulating an
autologous host response is controversial (Hewitt 1982), (tumour specific
'antigens' such as carcinoembryonic antigen and alphafetoprotein are
in fact tumour associated proteins but not antigens in the true sense).
Assuming that human tumours do in fact express novel surface antigens,
this antigen is processed by the reticuloendothelial system and can
lead to a humoral response mediated by the B (Bursa equivalent)
lymphocytes and plasma cells producing specific antibody directed towards
the antigens at the cell surface with subsequent destruction of the cell
by complement dependent mechanisms or by polymorphonuclear leucocytes
and macrophages. Alternatively, (Fig.l) the novel tumour antigen is
transported to the germinal centres in the lymph nodes and spleen by
accessory cells such as macrophages. This leads to the production of
a specific T (thymus dependent) cell response with the cytotoxic T
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tumour cell either directly or by the actions of its cellular products
(lymphokines) ,which can attract and then immobilise accessory cells such
as macrophages and polymorphs at the site of the abnormal cells to aid
in their destruction. As part of the control of the specific T cell
response, suppressor lymphocytes are also generated during the immune
response to a novel antigen, these cells regulate the specific T cell
response and may in fact block the action of cytotoxic T cells towards
the tumour cells possibly by binding with the antigen recognition site
of the cytotoxic T cell. The T lymphocyte is thought to require to
recognise the tumour specific antigen and major histocompatibility
antigens on the tumour cell surface simultaneously to produce cytotoxic
effects. This has been shown in mice with virally induced tumours
(Doherty et al 1976) but remains unproven for human tumours. The antigen
receptor sites on the lymphocyte are thought to be clonally distributed
and therefore after recognition of the antigen by the T lymphocyte, the
clone of lymphocytes with receptors for that particular antigen undergoes
/
clonal expansion with release of T lymphocytes directed towards the
antigen expressed on the tumour cell.
1.3 Neoantiqens on animal and human tumours.
Novel tumour specific antigens distinct from the major histocompatibility
antigens have been demonstrated on animal tumours. In 1943, Gross
demonstrated that isografts of a chemically induced tumour were immuno¬
genic and Prenn and Main (1957), amongst other workers showed that
inbred mice with identical histocompatibility antigens have novel
antigens associated with transplantable tumours.
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The presence of tumour specific transplantation antigens (TSTA) can
be demonstrated in vivo where prior exposure and therefore immunisation
against a specific tumour stimulates immunity to subsequent tumour
challenge with a tumour producing dose of live tumour cells. Tumour
specific transplantation antigens have been studied extensively in
animals with chemically induced tumours, particularly rodent sarcomas
and carcinomas induced by polycyclic hydrocarbons.. These tumours are
highly immunogenic and induce a strong tumour rejection response. In
these animals, immunisation by inoculation of attenuated tumour cell
preparations (e.g. irradiated cells) or tumour graft resection carried
out before tumour cell challenge, leads to failure of tumour
development in immunised animals compared to tumour growth in control
animals. This is taken to represent direct evidence of TSTA's on
these chemically induced tumours. (Boyse 1963; Klein et al 1960).
Tumours induced in animals with DNA viruses also express a tumour
specific transplantation antigen which is common to all tumours induced
by the same virus.
Spontaneously arising animal tumours however, are often either weakly
or non immunogenic (Hewitt et al 1976; Middle and Embleton 1981) and
these tumours are perhaps more representative of the situation in human
malignant tumours (Hewitt 1982) and therefore caution is required in
extrapolating the behaviour of animal tumour models which have been induced
with powerful chemical agents to human tumours.
Tumour specific antigens of human tumours have been implied by means
of various in vitro tests particularly the cytotoxicity assay. The
work of Hellstrom (1967), using a colony inhibition assay and Takasugi
and Klein (1970) with a microcytotoxicity assay was taken to show that
at the cell surface of human cancer cells, individually specific and
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organ specific tumour antigens were present to which the host mounted a
cell mediated immune response. Subseguent work, however, has shown
that peripheral blood lymphocytes show natural antitumour cytoxicity
(01Toole et al 1973) which must therefore question the results of
these original studies.
Using the above technigues and immunoflourescent staining techniques,
tumour specific antigens for human tumours have been detected for
melanoma (Lewis et al 1969; Shiku et al 1980), astrocytoma and renal
carcinoma (Shiku et al 1980). Lymphocytes from patients with a variety .
of tumours have been shown to undergo blastogenesis when cultured with
autologous tumour cells and also to develop cytotoxicity towards
autologous tumour cells used as targets (Vanky and Argov 1980; Vose et
al 1978) in cytotoxicity assays. This would suggest that the host lymphocytes
are sensitisied to autologous tumour cell antigens for these types of tumours.
In an attempt to show the presence of human tumour specific antigens
in vivo, researchers have injected tumour cell extracts subcutaneously
in patients to assess delayed type hypersensitivity reaction to supposed
tumour specific antigens. (Wells et al 1973; Hollinshead et al 1974).
Apart from the rather dubious ethical considerations of this type of
experiment, results have been difficult to interpret because of problems
with bacterial contamination of tumour cell extracts and the lack of normal
control tissue extracts, despite these objections however, a positive
response with induration at the injection site did appear to correlate
favourably with prognosis.
1.4 Humoral immunity against tumours.
In general, tumour specific cytotoxic antibodies have not been detected
in tumour bearing animals or humans. In rats with chemically induced
17.
sarcoma, resection of the tumour leads to the appearance of antibodies
in the serum and under laboratory conditions i.e. prolonged incubation
in the presence of complement in vitro, these antibodies have cytotoxic
activity.
In humans with malignant melanoma (Lewis et al 1969; Shiku et al 1980)
and renal carcinoma, (Shiku et al 1980) circulating antibodies can be
found in the course of the disease and following tumour excision which
in vitro can lyse tumour cells in the presence of complement. Tumour
specific antibody may have a role in antibody dependent cytotoxic cells
(ADCC) which are a lymphocyte subset capable of killing tumour cells in
the presence of such tumour specific antibody.
In experimental systems, antibody alone does not confer transplant
immunity to the animal and antibody may in fact enhance tumour growth
in the experimental animal (Moller 1964; Baldwin 1974), perhaps by
combining with the antigen on the tumour cell surface and blocking the
cytotoxic T cell mediated response.
It seems unlikely from the above evidence that tumour specific antibody
alone is a major cytotoxic mechanism against tumours.
1.5 Cellular immunity against tumours.
The classical concept of immune surveillance against tumours involves
the sensitised T lymphocyte as the effector mechanism. The cytotoxic
T cell is specifically programmed to recognise cells bearing abnormal
surface antigens and cause their death either directly or through the
action of lymphokines which direct accessory cells such as macrophages
to participate in cell killing.
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The classical concept of immune surveillance with the sensitised T
lymphocyte as the effector cell in the primary defence role against
developing tumour cells is now subject to question after consideration
of the following:
1. The delay between recognition of tumour antigen,processing of
antigen and production of sensitised T cells is in the order of
7 to 10 days and there is perhaps a place for a more rapid
primary defence mechanism of circulating cells which can recognise
abnormal cells, bind to them and kill them within hours rather
than days.
2. Experiments with T cell depleted mice (Stutman 1979) showed
resistance to challenge with syngenic tumour cells but impaired
rejection of allografts. Further experiments with nude mice,
which are congenitally athymic and hence have an absolute lack
of T cells,have failed to demonstrate an increased incidence of
spontaneous tumours over normal control animals (Rygaard and
Povlson 1976). This suggests the existence of a T cell independent
immune surveillance mechanism which has now been identified in the
mouse as the natural killer (NK) lymphocyte.
3. O'Toole and her colleagues (O'Toole et al 1973) have demonstrated
using a 4 hour chromium release cytotoxicity assay that the
cytotoxic cells present in patients with carcinoma of the bladder
were not T lymphocytes. In retrospect it would appear that these
cytotoxic lymphocytes were analagous to NK lymphocytes.
4. Perhaps the main objection to the conventional immune surveillance
theory.with the tumour cells expressing tumour specific antigens
leading to a specific T cell response directed against the tumour
cells is,the lack of evidence to support the existence of tumour
specific transplantation antigens as spontaneously arising animal and




Natural cytotoxicity or the ability of peripheral blood mononuclear
cells to recognise and kill tumour target cells without prior processing
of antigen was initially thought to be a laboratory artefact or the
"background noise" of the 4 hour chromium release assay of Brummer et al (1968)
used to detect specific cytotoxic activity of lymphocytes from tumour bearing
individuals. Lymphoid cells from normal patients with no prior exposure
to malignant disease or even to patients harbouring such disease were
used as "control" lymphocytes in experiments looking for specific
cytotoxicity against tumour target cells by lymphocytes from patients
with leukaemia. The lymphocytes from these control patients were found
to have considerable levels of cytotoxic activity against the leukaemia
cells used as targets (Rosenberg 1972). A further study by Kay (1974)
showed that lymphocytes from normal donors were cytotoxic to sarcoma
and carcinoma cells.
This property of natural cytotoxocity is now attributed to a subpopulation
of lymphocytes designated the natural killer or NK cell.
1.7 Characteristics of natural killer cells.
Natural killer (NK) cells have been found in the blood and spleen of
rodents, birds and man. The precise lineage of the NK cell has not yet
been defined completely but it appears that NK cells are a subset of
lymphocytes which are distinct from mature B and T cells. Surface
marker studies have been performed to relate NK cells to other lymphocyte
subsets. Virtually all human NK cells express surface receptors for the
Fc portion of lgG (Pross et al 1977) and 50% have low affinity receptors
for sheep erythrocytes and form rosettes (West et al 1977). NK cell
activity can be obliterated by anti-T cell serum plus complement
(Kaplan and Cauewaert 1978) which would support a prethymic origin
for these lymphocytes and NK cells may be prethymic T lymphocytes.
NK activity in rats and man is identified in the large granular
lymphocyte (LGL) fraction (Timonen et al 1981), which compromises about
5?o of circulating blood lymphocytes.
The NK cell may also be the same cell (killer or K cell) that mediates
antibody dependent cytotoxicity. This is supported by the findings of
receptors for the Fc fraction of lgG on NK cells which would enable
the same cell to produce cytotoxic effects by either interacting with
antibody coated target cells with the Fc receptor site or target ceils
with separate "NK receptors" (Koide and Takasugi 1977). Herberman and
Holden (1978) have shown that some target cells sensitive to NK activity
were able to inhibit antibody dependent cytotoxicity suggesting that
there are 2 separate receptor populations on the effector cells.
Studies by Santoni et al (1979), and Ojo and Wizzell (1978) using
nucleated target cells have shown similarity between NK and K cell types,
both have a similar ontogeny, tissue distribution and strain distribution
pattern. Both cell types are sensitive to in vivo cyclophosphamide
treatment with depression of cytotoxicity (Herberman and Holden 1979)
and both NK and K cell activity are stimulated by adjuvants such as
interferon (Ojo and Wizzell 1978).
1.8 Function and possible role for NK cells.
Natural killer cells have been shown to be cytotoxic to tumour cells,
virus infected cells and some normal cells such as bone marrow
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(Herberman and Ortaldo 1981). A postulated role for these cells is
that of a primary mechanism of host defence against developing tumour
cells (Herberman 1981)and a secondary role in preventing metastatic
spread of established tumours (Hanna and Fidler 1980).
In mice, NK activity first appears at 3 weeks of age, becomes maximal
at 8 to ID weeks and then gradually diminishes (Herberman and Ortaldo
1981). NK activity in the rat and hamster is not age restricted and
in man NK activity is found in foetal cord blood and remains present to
old age. Rosenberg et al (1973) have found in humans that natural killer
cell activity was maximal over 16 years of age and this probably does not
diminish significantly during adult life (Takasugi et al 1973). NK
activity of individual donors remains remarkably constant (Pross and
Baines 1982) but in females there may be slightly enhanced NK cell
activity in the second half of the menstrual cycle suggesting that
endocrine factors, particularly the female sex hormone oestrogen,may
influence NK cell behaviour (White et al 1982). There exists a diurnal
variation in T lymphocyte numbers but this is not found with NK
lymphocytes (Ritchie et al 1983) as defined by the monoclonal antibody
Leu 7.
One of the main objections to the T cell playing a major role in the
primary defence against developing tumour cells in humans is the
considerable dealy of 7 to 10 days between the initial contact with the
tumour specific antigen and also recognition of the major histocompatibility
complex on the surface of the tumour cell and the production of sensitised
lymphocytes which are either directly cytotoxic to the tumour or promote
cytotoxic activity of other cells. NK activity and target cell lysis,
however, occurs within hours of exposure of NK sensitive tumour target
cells to NK cells. NK sensitive cells are thought to possess NK
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surface receptors at which the NK cell binds. The findings by Jondal
and Targan (1978) that trypsin abolishes Nk activity is interpreted as
obliteration of these sites by the action of trypsin.
Vondinelich et al (1983) have suggested that the target structure on
susceptible cells which is recognised by the NK cell could be the
transferrin receptor sites. These workers found that target cell lines
with few or absent 0KT9+ cells (0KT9a is a monoclonal antibody which
recognises an epitope on the transferrin receptor) were resistant to
lysis by NK cells while those cell lines which carried the receptor
were largely NK sensitive. NK cell recognition of target cells was
inhibited with a trypsin cleaved fragment of the receptor protein with
a molecular weight of 70,000 purified from an 0KT9-bearing affinity column.
After recognition of the receptor site on the target cell surface
the NK cell binds to the target cell by forming adhesions, (Hiserodt
et al 1982), a process that takes 20 to 30 minutes and requires Mg+
j
to form a conjugate (see Fig.2). A lytic process which requires Ca
is then activated with subsequent lysis of the tumour cell within 3 to
6 hours. The mechanism of target cell lysis after binding of the NK
cell is still not clarified but may be performed by the enzymes (proteases
and phospholipases) thought to be present in the granules of the LGL's
which have NK activity (Goldfarb et al 1982). A protease inhibitor
(phenylmethyl-sulfanyl-flouride) has been shown by Hudig et al (1981)
to ablate NK activity suggesting that this enzyme may play a major
role in target cell killing. Recent work by Roder et al (1982) however,
has demonstrated that NK cells respond to NK sensitive target cells
with a rapid burst of oxygen metabolites which are involved in NK
mediated cytolysis and may in fact be the mechanism of cell killing.
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FIGURE 2.
ELECTRON MICROGRAPH OF A HUMAN LARGE GRANULAR (NK) LYMPHOCYTE (CENTRE) BINDING
TO A K562 TARGET CELL TO FORM A CONJUGATE.
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After target cell lysis, the NK cell dissociates from the lysed cell
and is capable of repeating the sequence of tumour cell recognitiion,
binding and lysis many times, this is referred to the recycling capacity
of the NK cell. Since this system of recognition and lysis of abnormal
cells is active within hours of introduction of these cells it should
constitute an effective mechanism in the initial phase of defence
against tumour formation with the specific T cell response becoming
active against the tumour at a later stage.
1.9 Evidence for NK cells as effector mechanisms in defence against
tumours.
There is mounting evidence that NK cells are an important part of the
defence system against developing tumours in both animals and man.
The evidence for the role of NK cells in resistance to in vivo tumour
growth in mice is summarised below:
1. There is a correlation between levels of NK activity and
resistance of growth of NK sensitive tumours in various strains
of mice.
2. Poor growth of NK sensitive tumours in nude mice (T cell deficient)
as compared to euthymic mice of the same strain.
3. More resistance to growth of tumours in young mice, at the peak
of NK activity, than in older mice.
4. T Cell deficient chimeras reconstituted with bone marrow from a
high NK strain, have high NK activity and increased resistance
to growth of NK sensitive tumours.
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5. More rapid and progressive growth of NK sensitive tumours in
beige mice which have no NK lymphocytes.
6. Close correlation between levels of NK activity and degree of
rapid clearance, of intravenous inoculated, radio-labelled NK
sensitive tumour cells, from the lungs and other organs.
Haller et al (1977) found that the growth of NK sensitive tumours in
mice was influenced by the NK cell status of the recipients in that
mice with high NK activity (nude mice, high NK strain, mice 5-8 weeks
of age) there was a lower incidence of progressive tumour growth after
tumour challenge than mice with low NK activity.
Mice subjected to lethal Xirradiation followed by reconstitution with
histocompatible bone marrow stem cells from low or high NK strains
produced T cell deficient mice with either high or low NK actvity
(Haller et al, 1977). Tumour resistance in vivo was found to be directly
correlated with high NK activity.
Beige mice are mice with a mutant gene (beige gene) which leads to a
complete and selective impairment of natural killer cell activity but
leaves the remaining forms of cell mediated immunity intact. Spleen
cells from these mice, which in normal mice are rich in NK cells, failed
to lyse YAC cells, a lymphoma cell line which is exquisitively sensitive
to NK cells (Roder et al 1979).
The human analogue of the NK cell deficient or beige mouse exists
in patients with the rare Chediak-Higashi syndrome. These patients have
a selective deficit in NK activity, but humoral and delayed type
hypersensitivity are normal (Roder et al 1979 ). They are known to have
a high incidence of lymphoproliferative disorders which is taken to
indicate a basic failure of the primary immune surveillance mechanism.
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Human NK lymphocytes have been shown in vitro to have activity against
tumour target cells derived from human tumours ranging from those cell
lines which are exquisitively sensitive such as the K562 cell line to
those which are completely resistant. The K562 cell line used in the
4 hour chromium release assay to detect cytotoxic activity of human
NK cells derives from the pleural effusion of a patient with myeloid
leukaemia in blast crisis. (Lozzio and Lozzio 1975).
In man, NK lymphocytes have also been demonstrated to have activity
against tumour cells derived from lymphoid malignancies (Rosenberg et al,
1972) and also some solid malignancies such as carcinoma of the colon and
lung (Vose and Moore 1980) malignant melanoma (Peter et al 1975,
Hersey et al 1980) and ovarian carcinoma (Mantovani et al 1983). It
is relevant that patients with malignant disease who have a large
"tumour burden" have low or undetectable levels of NK activity in the
peripheral blood (Pross and Baines 1976; Harowitz et al 1983). This
probably represents depression of NK activity by the large tumour load
rather than a primary immune defect involving NK cells allowing
uninhibited tumour growth. Studies of fresh human tumours have attempted
to demonstrate NK activity in tumour infiltrating lymphocytes however, either
very low or absent NK activity is usually reported, (Vose 1980;
Bland et al 1981; Becker S 1980), although studies from our laboratory
have found significant natural cytotoxicity of tumour infiltrating
lymphocytes (from tumours removed from patients studied in this thesis)
in about 30% of colorectal tumours studied (Clegg 1983).
1.10 Natural killer lymphocyte activity and patient survival.
The results of some studies into human NK lymphocyte activity have
suggested a correlation between levels of NK activity and subsequent
prognosis. In patients with malignant melanoma, those patients with
high levels of NK activity following removal of local recurrent tumour
developed significantly fewer distant metastases than those with low NK
activity. (Hersey et al 1982). NK activity in these patients appeared
also to correlate with thickness of the tumour which is the main factor
in determining the prognosis of these patients. Other studies also
suggest some correlation between host survival and host levels of NK
activity although the evidence for this is not totally consistent
(Karre et al 1980; Gorelik et al 1981) and possibly natural resistance
to tumours as mediated by NK lymphocytes is a heterogenous phenomenon.
1.11 NK cell activity in prevention of tumour metastases.
the natural killer lymphocyte in addition to T cells and macrophages
may be an effective defence against intravascular tumour metastases
even when the tumour cells have overcome the natural resistance mechanisms
which have failed to prevent its primary growth. Cells from a malignant
tumour have the capacity to invade endothelial lined surfaces such as
veins and lymphatic channels with the release of tumour cells into the
venous and lymphatic circulations which can then form distant tumour
metastases. (See Fig.3). Haematogenous metastases form when circulating
emboli of tumour cells impact in a capillary circulation such as the
liver or lung, the preferential site for tumour cell arrest is usually
the first capillary circulation reached after initial venous invasion.
Clumps of tumour cells rather than individual cells are most likely to
form metastases (Liotta et al 1976)which become covered with a sheath of
fibrin from fibrinogen in the blood, then invasion of the capillary wall
occurs with the subsequent development after tumour cell replication of
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may be kept dormant and localised if the tumour cell emboli can be
lysed by circulating macrophages, activated T cells or NK cells.
Riccardi et al (1979), were the first to show that in mice there was
an effective clearance of radio labelled tumour cells from the lungs and
other organs within 2 hours of intravenous inoculation, this time scale
is too short for macrophages or other lymphoid cells to be effective
and therefore the authors concluded that the NK cell was the responsible
effector cell in this situation, this premise is strengthened by the
fact that the rapid clearance from the lungs was related to the pre-
existence of NK cells in that organ.
Hanna et al (1980) confirmed that clearance of radio labelled tumour
cells correlate with NK activity and also that tumour resistance of
cyclophosphamide treated mice (which have depressed NK activity) can be
restored by systemic transfer of spleen or bone marrow cells which
repopulate the mice with NK cells.
It is of interest therefore that beige mice which have a selective
deficit in NK activity had increased metastatic spread of Lewis lung
tumour when implanted subcutaneously (Salomen et al 1980) yet nude mice
which are T cell deficient but possess normal NK activity did not
develop tumour metastases. (Freedman et al 1976).
In humans, the role of NK cells in the prevention of haematogenous
tumour metastases is unknown but the requirement for an effective
intravascular defence system is self evident. The finding of tumour cells
in the circulating blood, particularly during surgical manipulation of
the tumour, is well documented (Salsbury et al 1965; Roberts et al 1960)
and the effect of anticoagulants in reducing metastases (El Rifi et al
1965) may operate by delaying arrest and implantation of tumour cells
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by preventing the formation of a fibrin coat such that the intravascular
tumour defence systems (NK cells, T cells and macrophages) have more
time to eliminate tumour cell emboli. If NK cells do have a role in
prevention of metastases in man, patients whose NK activity is depressed
in some way by a large tumour load may be more susceptible to sub¬
sequent development of distant haematogenous metastases.
1.12 Modulation of NK activity.
NK cells are similar to other biological systems in that they are subject
to factors which enhance NK activity as well as inhibiting factors which
control the overall activity of these cells.
Enhancement of NK activity. Interferon and interferon inducers.
Interferon was first identified by Isaacs and Lindenmann in 1957. The
interferons are now known to be a family of glycoproteins (a, f3 and ^)
which are synthesised by cells in response to viral -infection, immune
stimulation and a variety of chemical inducers. The interferons have
been found to have a wide range of biological activity apart from their
antiviral action including inhibition of tumour cell multiplication
(Gesser 1977). enhanced lymphocyte cytotoxicity (Heron et al 1976),and
macrophage activation (Rabinovitch et al 1977) which has lead to their
use as a potential antitumour agent.
Interferon is the most potent known stimulator of natural killer cell
activity (Herberman et al 1979) and known inducers of interferon such as
bacterial adjuvants (BCG), viruses, tumour cell lines (Djeu et al 1980)
and chemical agents such as polynosinic acid - polycytidytrie acid
(poly 1:C) (Zarling et al 1980) can also enhance NK activity.
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Interferon boosts NK activity in rodents and man by recruitment of
NK cells, possibly pre NK cells to mature cells with cytolytic activity,
and increasing the kinetics of target cell lysis by improved binding
to target cells (Stewart et al 1982) and increased recycling ability
of effector cells (Ullberg et al 1981) to enable them to detatch from
the lysed cell and"bind and kill further target cells. Interferon
inducers act by stimulating interferon production by macrophages or
lymphocytes: in the mouse there is an absolute requirement for monocytes
to be present for enhancement of NK activity to occur, but in man
however certain interferon inducers such as poly IC are able to enhance
NK activity without accessory macrophages in vitro, (Koren et al 1981)
possibly by direct stimulation of NK cells to produce interferon. Addition
of anti interferon antibodies to human and animal test systems causes a
failure of enhancement of NK activity.
Large tumour burdens (Pross and Baines 1976; Kadish et al 1981) and
severe protein calorie malnutrition (Salimonu et al 1982) in man is
associated with a refractory enhancement response to exogenous interferon
and this may be a factor in tumour dissemination and perhaps increased
risk of infection in these patients.
Inhibition of NK activity.
Direct inhibition.
Prostaglandins (PG's) cause marked depression of NK activity in vitro
(Salimonu et al 1982) when added to the test systems used to detect
cytotoxic activity of NK cells although the mode of action is unknown.
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Brunda et al (1980) examined the effect of prostaglandins on murine
natural killer cell activity and found that PGE^, PGE^, PGA, or PGA^
were inhibitory to NK activity but PGB^, PGB2, PGE^a or PGp2a did not
cause significant inhibition, further support that some PG's are
inhibitory to NK cells comes from the work of Koren et al (1981), who
showed that monocytes incubated with poly l.C. produce PG's and
inhibit NK activity but this effect was reversed by adding indomethicin,
a known prostaglandin synthetase inhibitor, to the test system.
It is well established that malignant tumours of the breast (Bennett et
al 1977) and lung (Bennett et al 1982) contain high levels of prost¬
aglandin like material compared to normal breast or lung tissue. The
level of this substance correlates directly with tumour invasion and spread
and could be seen as an inhibitory mechanism to the immune defence role
of the NK lymphocyte. Corticosteroids, some chemotherapeutic agents
(e.g. cyclphospharnide) and X irradiation are also known to suppress or
ablate NK cell activity. (Hochman et al 1979; Djeu ,et al 1979;
Oehler et al 1978).
Inhibition by suppressor cells.
Suppressor cells induced by various treatments have been shown to depress
NK activity although the type of cell responsible is variable. Suppression
is not seen in nude mice suggesting that the suppressor activity in mice
is mediated by suppressor T cells, (Savary and Lotzova 1978). Suppressor
cells induced in mice by pyran copolymer have macrophage type
characteristics in that they are capable of phagocytosis. (Santoni et al
1979).
In humans, suppressor cell activity to NK cells has been shown in
malignant pleural effusion (Uchida and Nichsche 1981) and also after
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anaesthesia and surgery in patients with breast cancer (Uchida et al
1982). This effect was thought to be mediated by suppressor monocytes.
Prostaglandins (PG's) produced primarily by mononuclear phagocytic cells
(Kurland and Bockman 1978; Kennedy et al 1980) are known to be potent
inhibitors of NK activity and they are thought to be the likely mechanism
of inhibition of NK activity by suppressor cells.
Sequestration of NK cells.
NK cells may be sequestered in tumours which could account for the
depression of NK activity seen in many tumour bearing patients,
particularly those with advanced malignancy. Studies of tumour infiltrat¬
ing lymphocytes (TIL's) of both animal and human tumours have failed to
demonstrate significant levels of NK activity (Vose 1980; Bland et al 1981;
Becker 1980) and many studies have found NK activity to be totally absent
in lymphocytes isolated from tumours although recent work in our
laboratory has shown significant NK activity in TIL's in 30?o of human
colorectal tumours studied. The possibility still remains however that
NK cells are sequestered in the tumour but their activity is inhibited
by products from the tumour cells per se or other intratumour cells such
as suppressor cells.
Reduction of recycling capacity.
The ability of an NK cell to bind to and cause target cell lysis then
release and bind to subsequent tumour target cells is called the recycling
capacity of the cell. This has been shown by kinetic studies to be
reduced in patients with advanced cancers (Steinhauer et al 1982) and
may be yet another factor in the reduced cytotoxic ability of NK cells
found in patients with advanced malignant disease.
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1.13 Intratumour NK activity.
It might be expected that if NK cells play a prominent early role in
immune surveillance and defence against developing tumours, NK activity
would be found in lymphocyte populations isolated directly from tumours.
In many studies, however, NK activity has not been detected in tumour
infiltrating lymphocytes in humans although NK activity in the
circulating blood lymphocytes is within the normal range for patients
without malignant disease. It has been proposed that defective NK
activity of TIL's is due either to suppressor cells or factors operating
on the TIL's or a low number of effector cells in the tumour substance
(Introna et al 1982). It is perhaps not unexpected in that for a tumour
to develop to such a size that it requires surgical resection, the immune
defences have failed and the NK cell response has been overwhelmed. NK
cells in this situation may still have considerable importance in the role
of prevention of metastatic spread of the tumour by recognising and
destroying tumour cell emboli.
The possible mechanisms for direct intratumour suppression of NK activity
are thought to be either the generation of prostaglandins by intratumour
host cells (suppressor cells) or perhaps even the tumour cells per se.
Golub et al (1982) using a single cell assay against K362 targets has
shown that low activity of TIL's to tumour target cells was not due to
low numbers of effector cells but due to the effect of suppressor
substances.
Further research is required to define the precise mechanisms of
intratumour NK suppression.
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1.14 The effect of anaesthesia and surgery on immune systems.
The majority of patients with malignant disease of the gastrointestinal
tract have exposure to a general anaesthetic and a surgical procedure
either for exploratory purposes or excision of the primary tumour.
Evidence from experimental animal systems (El Rifi et al 1965;
Gottfried et al 1961) suggests that either anaesthesia or the surgical
stress of the operation can be associated with dissemination of the
primary tumour and development of metastases, this has also been shown
for human patients (Gordon-Taylor 1948). The mechanism of tumour
dissemination does not appear to be entirely due to release of tumour
cell emboli during surgical manipulation of the tumour (Salsbury et al
1965; Roberts et al 1960) but also due to an observed depression of the
overall immune response.
There is a decrease in circulating T and B lymphocytes following
anaesthesia and surgery (Slade et al 1975) with reduced lymphocyte
responsiveness to mitogens and antigenic stimulation. Delayed hyper¬
sensitivity reactions are reduced or abolished following surgery indicating
a basic depression of the cell mediated immune response (MacLean 1979).
Cytotoxicity of lymphocytes to autologous tumour target cells is decreased
post operatively in patients with breast cancer (Vose and Mougdil 1975)
and malignant melanoma (Cochran et al 1973) and antibody dependent cyto¬
toxicity is also decreased post operatively in previously immuno suppressed
cancer patients (McCredie et al 1979). Neutrophil chemotaxis and
phagocytosis are also reduced after surgery but return to normal levels
within a few days of the surgical operation.
In order to dissect the precise relationship of anaesthesia and surgery
to this depression of immunity, in vitro studies of commonly used
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anaesthetic agents have shown a slight reduction of the phytohaemagglutin
response (a known mitogen) of lymphocytes and the leucocyte migration
inhibition test. The main immune suppression however would appear to
be due to the stress of the surgical procedure with for example the
degree of depression of the lymphocyte response to phytohaemogglutinin
being proportional to the degree of surgical stress (Cullen and Van Belle
1973). In vitro responsiveness to phytohaemagglutinin was found to be
more depressed in cancer patients than patients with benign disease
following operation.
The immune depression seen after surgery is very similar to that seen
after severe trauma or burns and would therefore appear to be related
to the stress response to surgery. Release of corticosteroids,
catecholamines and prostaglandins occurs after surgical stress and
trauma and these agents may cause immune depression. Suppressor cells
have also been found in mice (Waugh et al 1982) and human patients
following operation (Baker et al 1979; Uchida et al 1982). These cells
have macrophage activity and could inhibit the specific T cell response
and NK cell activity.
1.15 The effect of anaesthesia and surgery on NK cell activity.
Uchida et al (1982) have shown a decrease in NK activity as measured
by the 4 hour chromium release assay using K562 target cells in female
patients with breast carcinoma following mastectomy. The NK status of
these patients before surgery was comparable to benign controls. The
depression of NK activity occurred 2 to 3 days following surgery and
appeared to be mediated by suppressor monocytes in that 24 hour pre
culture of patients cells with NK cells from normal controls suppressed
the activity of these cells.
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The response of patients NK cells to anaesthesia per se and the response
during the period of surgical operation remains unknou/n.
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AIMS OF THE PRESENT STUDY.
The purpose of the study is to determine the effect of malignant tumours
in the gastrointestinal tract on natural killer cell activity of the
human host. The primary treatment modality of these patients is surgical
which entails an operative procedure under general anaesthetic, therefore
the behaviour of natural killer lymphocytes in patients undergoing general
anaesthesia and surgical operation will be studied and compared to a
control group of patients with benign disease also undergoing general
anaesthesia and surgical operation. Surgery remains the main hope of
cure for most patients with gastrointestinal malignancy, and it can be
proposed that enhancement of natural cytotoxic mechanisms, such as those
mediated by the NK cell, may help reduce tumour metastases and hence
improve patient survival. The specific questions that this study proposes
to answer are:
1. Do malignant tumours of the gastrointestinal tract directly modify
natural killer cell activity, and if so, what is the likely
mechanism?
2. What is the effect of general anaesthesia and surgery on the
cytotoxic potential of natural killer lymphocytes? Does the
type and route of anaesthesia influence natural killer cell activity
of peripheral blood lymphocytes?
3. Is there any likely therapeutic manoeuvre which can enhance natural
killer cell mediated cytotoxicity to tumour cells in the intra¬
operative period when it is known that large numbers of tumour
cells from the primary tumour are present in the circulation?
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PATIENTS, MATERIALS AND METHODS.
1. Patient Details.
2. General Laboratory Equipment.
i. Chemicals
ii. Deionised and glass distilled water
iii. Glassware
iv. Plastic and disposable hospital and laboratory equipment
3. Stock Solutions.
i. Heparin
ii. Lymphocyte separation medium
iii. New born and foetal calf serum
iv. Trypan blue
v. Crystal violet
vi. Phosphate buffered saline
vii. Trypsin
viii. Versene
ix. Human lgG (Cohn fraction II)
x. Iodogen










v. Tumour, cell line - K562
vi. Raji cell line
vii. Maintenance of tissue culture - stationary suspension
cultures
viii. V/iable cell counts
ix. African Green Monkey kidney cells
x. Baby hamster kidney cells
6. Semliki Forest Virus Culture.




ii. Transport of blood and tumour samples
iii. Anaesthetic techniques
iv. Lymphocyte separation from whole blood
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8. Experimental Methods Continued.
v. 4 hour Cr release cytotoxicity assay
a. Labelling of tumour cells
b. ^Cr release assay for separated lymphocytes
c. "^Cr release assay for whole blood
vi. Preparation and storage of plasma samples
vii. Addition of plasma samples to control PBL's
viii. Heat treatment of plasma samples
ix. Monoclonal antibody characterisation of leucocytes
x. Morphological characteristics of leucocytes
xi. Raji cell assay for immune complexes
xii. Interferon assay
xiii. In vitro incubation of PBL's with exogenous interferon
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TABLE I (a)
Details of patients with malignant disease of the large bowel,
Patient Age Sex Tumour Site
JC* 58 M Adenocarinoma Colon
RR* 72 M Adenocarinoma Rectum
FO* 86 F Adenocarcinoma Colon
GW* 8D M Adenocarinoma Colon
DG* 58 M Adenocarcinoma Rectum
JB* 69 M Adenocarcinoma Colon
WW* 71 M Adenocarcinoma Colon
FW* 88 M Adenocarcinoma Colon
NF* 84 F Adenocarcinoma Colon
WD* 65 M Adenocarcinoma Colon
DP* 55 M Adenocarcinoma Colon
MS* 65 F Adenocarcinoma Colon
NW* 82 F Adenocarcinoma Colon
AH* 65 M Adenocarcinoma Colon
AP* 63 M Adenocarcinoma Colon
GH* 59 M Adenocarcinoma Colon
EM 77 F Adenocarcinoma Rectum
JH 60 F Adenocarcinoma Rectum
HC 63 M Adenocarcinoma Rectum
* Aortic,tumour draining venous blood and venous blood
from adjacent bowel sampled.
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TABLE I (b)
Details of patients with malignant disease
of the stomach.
Patient Age Sex Tumour
PW* 32 M Lymphoma
JC* 57 M Adenocarcinoma
WN* 52 F Adenocarcinoma
FP* 71 M Adenocarcinoma
BR* 69 F Adenocarcinoma









* Aortic, tumour draining venous blood and
venous blood from adjacent stomach sampled.
46.
TABLE II.
Details of patients with benign disease.
Patient Age Sex Diagnosis
MB* 67 M Gallstones
NT* 68 F Gallstones
GH* 57 M Duodenal ulcer
GB* 40 M Duodenal ulcer
EB* 66 M Gallstones
MG* 41 F Gallstones
WW* 22 M Duodenal ulcer
PB* 34 F Gallstones
MT* 71 F Gastric ulcer
EA* 68 F Gastric ulcer
DS 51 M Colostomy
KN 28 M Colostomy
MS 62 F Gallstones
BI 57 F Benign weight loss
AJ 43 F Gallstones
MH 55 F Gallstones
CS 65 F Gallstones
MB 60 F Gallstones
MC 80 F Villous adenoma rectum
MS 64 M Gallstones
* Aortic.colon and stomach draining venous blood samples
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1. PATIENTS, MATERIALS AND METHODS.
Patients.
The study group consisted of 29 patients with histologically proven
malignant tumours of the stomach or large bowel undergoing either
resection of the primary tumour or exploratory laparotomy. In 22
patients it was possible to sample blood from veins directly draining
the tumour. 19 patients,with mainly benign upper abdominal conditions
(gallstones, duodenal ulceration) requiring surgical operations were
also studied. In 10 of those patients aortic>stomach and colon draining
venous blood was sampled. Patient details for both groups are given in
Tables I (a), I (b) and II.
Informed consent was obtained from each patient prior to study and the
protocol for the study was approved by the local hospital ethical
committee.
2. MATERIALS AND METHODS.
General Laboratory Equipment,
i. Chemicals.
General laboratory reagents of ANALAR grade were used throughout
the laboratory part of this study.
ii. Deionised and Glass Distilled Water.
This was prepared by passing water directly from the main supply
through an elgastat deionisation unit with a specific conductivity
of >1.0 x 10^ ohms/cm^. T issue culture media preparation and
most other solutions were prepared from 500 ml volumes of glass
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distilled water which was sterilised by autoclaving at 20 psi for
20 minutes.
iii. Glassware.
Pyrex glassware was used which was cleaned by boiling and washing
in a commercially available detergent. It was then rinsed several
times with tap water followed by deionised water. All glassware
was dried in a hot air oven at 80°C and then sterilised in a hot
air oven at 160°C for 2 hours.
iv. Plastic and Disposable Hospital and Labroatory Equipment.
Plastic syringes(10 ml, 20 ml and 60 ml volumes) and disposable
needles (25G and 19G) were used for the hospital collection of
blood samples. These were obtained by the hospital pharmacy from
Becton Dickinson and Company, Middlesex, England. Plastic
universal containers (30 ml), plastic centrifuge tubes and plastic
bijoux were purchased from Sterilin Laboratories, Middlesex,
England. Round bottomed microwell test plates with 96 wells/plate




Heparin (1000 units/ml) was used to "lubricate" the plastic
syringes used for venepuncture and was added to the blood samples
at 0.1 ml per 10 ml of whole blood to prevent clotting during
transport and subsequent assay of cytotoxicity. This was obtained
by the hospital pharmacy from Weddel Pharmaceuticals Ltd., London,
who also supplied the laboratory with heparin at a concentration
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of 25,000 unit/ml, u/hich was diluted to give a final conentration
of 100 units/ml. Heparin was stored at 4°C until required.
ii. Lymphocyte Separation Medium (LSM).
This was obtained from Flow Laboratories Ltd., Irvine, Scotland.
LSM is an aqueous solution consisting of 5.7 g of a high density
sucrose - epichlorohydrin polymer (Ficoll 400 Pharmacia Fine
Chemicals) and 9 g of sodium diatrozate per 100 mis, giving a
density of 1.077 ± 0.001 g/ml and an osmolality of 270-300 mOsm/kg.
It was stored in the dark at room temperature.
iii. Newborn Calf Serum (NBCS).
This virus and mycoplasma free serum was supplied by Flow
Laboratories Ltd., Irvine, Scotland and stored at -20°C until
required. Heat inactivation was performed by leaving the thawed
serum in a 56°C water bath for 40 minutes.
iv. Trypan Blue.
Trypan blue powder was purchased from BDH Limited, Poole, England.
A solution of one per cent was prepared in phosphate buffered saline
and the excess solid residue was filtered off. The clarified
solution was dispensed in 2-3 ml volumes, autoclaved at 10 psi and
stored at 4°C.
v. Crystal V/iolet.
This was purchased from BDH, Poole, Dorset. A l?o solution by weight
was prepared in phosphate buffered saline and stored at room
temperature.
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vi. Phosphate Buffered Saline (PBS).
This was prepared from tablets supplied by Oxoid Ltd., London.
The solution conformed to the formula described by Dulbecco et al
1954. The solution was sterilised by autoclaving at 10 psi
for 10 minutes and stored at room temperature.
vii. Trypsin.
Trypsin solution was prepared by dissolving 2.5 gm of trypsin
(Difco 1:250) in one litre of PBS and stirred with a magnetic
stirrer at room temperature. The clarified solution was then
sterilised by filtration through a Seitz filter, dispensed into
10-20 ml aliquots and stored at -20°C.
viii. Versene.
The di-sodium salt of ethynal diamine-tetracetic acid (versene)
was added to PBS at a concentration of 0.02% and the pH adjusted
to pH 7.2 - 7.4 with N10 sodium hydroxide. The solution was
dispensed in 10 ml aliquots, autoclaved at 10 psi for 10 minutes
and stored at 4°C.
ix. Human 1 qG (Cohn Fraction II).
This was obtained in saline (20mg/ml) from Plow Laboratories, Irvine
and freed of aggregates by centrifugation at 100,000 x G for 90
minutes. The protein content was adjusted to 6.5 mg/ml of saline
and the solution stored in aliquots of 0.2 ml at -70°C.
x. Iodoqen.
This was supplied as Iodegen in 1 gm quantities by Pierce Chemical
Company,Rockford, Illinois , U.S.A.
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xi. Staphylococcal Protein A.
This was obtained from Pharmacia Fine Chemicals, Uppsala, Sweden,
as Protein A in 5 mg freeze dried packs.
4. INTERFERON PREPARATION.
Human Lymphoblastoid (Namalva) Interferon (HIF).
A vial of freeze dried material (batch 4656/6) of human leucocyte a
interferon was donated by Drs. Fautes and Johnston, Wellcome Research
Laboratories, Beckenham. The vial contained approximately 6 x 10^
interferon units of a specific activity of 6 c 10"* units/mg of protein.
The freeze dried interferon was dissolved in 1 ml of glass distilled
water and then diluted down futher to be stored at a concentration of
20,000 units HIF/0.1 ml vial at -80°C.
5. TISSUE CULTURE.
i. Media - RPMI 1640
RPMI 1640 (10 x concentrate) minus L-glutamine was supplied by
Gibco-Biocutt (Europe) Glasgow, Scotland and made up as follows.
RPMI 1640 (10 x concentrate) 50.0 ml
Calf serum 50.0 ml
Sodum bicarbonate (4.4?o) 10.0 ml
1M Hepes buffer 10.0 ml
200 mM L-glutamine 10.0 ml
Glass distilled water 355.0 ml





This was prepared using minimal essential medium concentrate from
Flow Laboratories Ltd., Irvine, Scotland.
Maintenance medium (10 x concentrate) 50.0 ml
Calf serum 20.0 ml
Glass distilled water 450.0 ml
Antibiotics : Penicillin 0.5 ml
Streptomycin 0.5 ml
iii. Medium 199.
This was prepared using medium 199 concentrate from Flow Laboratories
Ltd., Irvine, Scotland. It was made up according to the following
formula.
Medium 199 (10 x concentrate) 50.0 ml
Glass distilled water 450.0 ml
Sodium bicarbonate solution (7.5?o) 5-10ml
Antibiotics : Penicillin 0.'5 ml
Streptomycin 0.5 ml
iv. Sterility Checking.
a. Thioqlycolate Broth. This broth was prepared by dissolving
one tablet (Oxoid Limited, Hampshire) in 10 ml of deionised
water, the solution was then autoclaved at 15 psi for 15 minutes
and kept at room temperature until required for sterility
monitoring of all tissue culture media.
b. Sterility Control. This test was performed on every individual
new bottle of tissue culture media prior to use. 10 ml of
sample media was taken aseptically and inoculated into each of
2 bottles of thioglycolate broth, one of which was incubated at
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37°C, and the other at 33°C. After 7 days, if the broth
remained clear, the medium was considered sterile and used
throughout.
v. Tumour Cell Line - K562.
This cell line comes originally from the pleural effusion of a
leukaemia patient in blast crisis. The K562 cell line was donated
by Dr. D. Jones, Department of Pathology, University of Southampton
Medical School. This in vitro tumour cell line was maintained as
a stationary suspension culture in RPMI-1640 (with 10% NBC5 .
(Lozzio and Lozzio 1975).
vi. Raji Tumour Cell Line.
Raji cells, which are derived from a Burkitts' lymphoma, were
cultured in RPMI 1640 (with 10% NBCS) as a stationary suspension
(The Raji cells were obtained from Flow Laboratories, Irvine,
Scotland). Cells used in the assay were harvested 72 hours after
initiation of the culture.
vii. Maintenance of Tissue Culture.
Stationary suspension cultures. All these lines were subcultured
regularly when confluent. Bottles were generally split in a ratio
of 1 to 5 with fresh culture medium and the cells reincubated at
37°C.
viii. Viable Cell Counts.
Viable cell counts of tumour cell suspension were performed using
Trypan Blue exclusion, where dead cells take up the dye within a
few seconds and appear blue under the microscope, making them easily
distinguishable from viable cells. One part cells (0.2 ml) to 1
part Trypan Blue (0.2 ml) to 8 parts (1.6 ml) of phosphate buffered
54.
saline were mixed and placed under the coverslip of an improved
Neubauer Counting Chamber(Hawskly Limited, Lancing, Sussex).
Magnification at 100-400 times was used to count the cells and cell
suspensions of less than 90?o viability u/ere discarded.
Lymphcoyte populations were also counted using the same technique.
ix. African Green Monkey Kidney Cell Line. Method of Subculture.
This cell line was obtained from Flow Laboratories, Irvine.
Confluent cell monolayers were washed in PBS and then 10 ml of
trypsin/versene mixture (1:1 ratio) was layered onto the monolayer.
After gentle agitation the mixture was decanted leaving a film
over the cell monolayer which was then incubated at 37°C for 1
hour. The cells were then washed off the glass culture bottle
with Medium 199, counted and a cell suspension prepared and
transferred to a glass culture bottle, incubated at 37°C which
resulted in a confluent monolayer in 3 to 4 days.
x. Baby Hamster Kidney Cells BHK(21).
Cell cultures were obtained from Flow Laboratories, Irvine,
Scotland. These were cultured as monolayers with trypsin into
minimal essential medium at 37°C. Confluent monolayers were obtained
in 3 to 4 days.
6. SEMLIKI FOREST VIRUS.
The Semliki Forest virus was a gift from Dr. M.D. Johnston, Wellcome Research
Laboratories, Beckenham, Kent.
Baby hamster kidney cells (BHK21) were grown to confluent monolayers in a
20 oz glass bottle. One ml of 1/100 dilution of stock solution virus was
inoculated onto the cell monlayer, allowed to adsorb for 1 hour at 37°C and
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then the inoculum removed. Thirty ml of medium 199 containing 2% NBCC
was added to the culture bottle which was incubated for 36 hours at
37°C. The supernatant containing the virus was then removed, clarified
into aliquots and stored at -80°C prior to use.
7. MONOCLONAL ANTIBODIES.
Monoclonal antibodies (Becton Dickenson) were supplied by Labarotory Impex,
Lion Road, Twickenham, London. The following monoclonal antibodies were
used to identify the lymphocyte populations studied.
Leu 4 (pan T lymphocytes)
Leu 7 (NK lymphocyte)
8. EXPERIMENTAL METHODS.
i. Blood Sampling.
a. Peripheral venous blood. Five to 20 ml of peripheral venous
blood was taken from the antecubital vein using a tourniquet
and venepuncture with a 19G needle. 5 ml samples were
placed into lithium heparin tubes and 20 ml samples placed
in a sterile universal container with 0.2 ml of heparin added.
These samples were taken before induction of anaesthesia and
prior to surgery.
b. Samples taken during operation. Blood (2-5ml) was taken from
the aorta, this was assumed to be equivalent to the arterial
supply to the tumour in terms of NK cell activity, using a 25G
needle and 10 ml syringe "lubricated" with heparin. The largest
vein draining the tumour was also sampled using an identical
technique and also a vein draining macroscopically normal
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adjacent tissue (stomach or colon).
In the control group of patients u/ith benign disease samples
were taken from aorta, a stomach vein and a colon vein.
Peripheral venous samples were also taken during surgery one
hour after induction of anaesthesia and start of surgery.
ii. Transport of blood samples.
The blood samples were either sent for analysis to the Virology
Department, Medical School, Sheffield on the same day or kept
overnight at A°C for analysis the following morning.
iii. Anaesthetic Techniques.
Inhalation anaesthetics. After intravenous induction with thiopentone,
a balanced gas anaesthetic of nitrous oxide, oxygen and halothane
was given with neuromuscular blocking drugs and artificial ventilation.
Infusion anaesthetics. A total intravenous anaesthetic technique
using Etomidate/Fentanyl and neuromuscular blocking drugs with
artificial ventilation of the lungs was used in some patients with
benign and malignant disease. A two step schedule was used with
etomidate 100 yg/kg/minute and fentanyl 1 yg/kg/minute given for
ten minutes followed by a maintenance dose at a one tenth of this rate.
iv. Lymphocyte Separation.
Whole blood. Twenty to AO ml of heparinised whole blood was
layered in 5 ml volumes on top of A ml of L5M in a centrifuge tube.
The samples were centrifuged at A00 g for 30 minutes at room
temperature which resulted in the lymphocytes forming a distinct
layer at the interface of the plasma and LSM. This layer of cells
was drawn up into a Pasteur pipette taking minimal amounts of plasma
and LSM. The lymphocyte suspension was washed 3 times in RPiTI
(Boyum 1968) counted and resuspended in a known volume of RPMI.
v. 4 Hour ~^Cr Release Cytotoxicity Assay.
a. Labelling of Tumour Target Cells.
Target cells were spun down and resuspended in 0.2 ml of RPMI and
labelled with Na2~'~'"CrO (Radio Chemical Centre, Amersham,
Buckinghamshire) by adding 100 uCis/0.1 ml of the isotope and
incubating for 1 hour at 37°C. These cells were then washed 3
times, reincubated in the fresh medium for 1 hour, washed (x3) and
a trypan blue count performed. The cells were then resuspended
in RPMI at a concentration of 10^ cells/ml.
b. ~^Cr-reIease Assay for Separated Lymphocytes.
Effector cells were adjusted to the reguired cell concentrations to
give effector:target ratios of between 50:1 and 6:1 (effector cells
at 5 x 10^ cells/ml to 6 x 10^ cells/ml). 0.1 ml of effector cells
and 0.1 ml of "'"'"Cr-labelled target cells were added (in triplicate)to
round bottomed microtest plates(Falcon Products).In those tests where
the effect of plasma from the patients with malignant disease was
being studied, 0.05 ml of effector cells and 0.05 ml of plasma
were added to 0.1 ml of ^Cr-labelled target cells. The test plates
were incubated at 37°C in a 5% Zo^/9b% air atmosphere for 4 hours.
The cells were sedimented by centrifugation at 200 g for 5 minutes
and 0.1 ml of supernatant removed into separate wells. The plates
were dried in an oven, sprayed with Opsite plastic spray and then
individual wells counted on a Packard gamma spectrophotometer. The
~^Cr release was directly proportional to target cell killing and
was counted as follows:
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% "^Cr release = 2 x (%5N) ^gg
(cells + %SN) + (%5N)
where SN = supernatant.
Percentage cytotoxicity was calculated as follows:
% cytotoxicity = test release - spontaneous release ^ ^gg
100 - spontaneous release
c. "^Cr-release Assay for Whole Blood.
Whole blood was serially diluted at 1/2, 1/4 and 1/8 dilutions with
RPMI (10?o NBC5) and 0.1 ml volumes placed in test wells with 0.1 ml
of "'"Cr labelled target cells (Rees and Platts 1983). The percent
"^Cr release and percentage cytotoxicity was calculated in the
identical manner for the assay for separated lymphocytes. The
cytotoxic capacity of whole blood to K562 targets correlates well
with the cytotoxicity of separated PBL's (Rees and Platts 1983).
vi. Preparation and Storage of Plasma Samples.
Whole blood was centrifuged at 400 g for 20 minutes, the plasma
collected and then further centrifuged at 400 g, for 30 minutes.
1 ml aliquots were taken into sterile glass tubes which were
stored at -80°C prior to study.
vii. Addition of Plasma Samples to Control PBL's.
PBL's were separated from the peripheral venous blood of normal
controls (Laboratory volunteers) as described previously. Fifty
microlitres of plasma from the peripheral venous blood, or tumour
draining venous blood of the tumour patients were added to 50yl
control lymphocytes at concentrations of 1 x 10^ and 5 x 10^ cells
per ml and pre incubated for 1 hour at 37°C in a humidified 95% air
5% CO2 atmosphere prior to cytotoxicity assay. In addition 50 yl
of plasma from the peripheral venous blood, stomach and colon
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draining venous blood of patients with benign disease were added
to 50 pi of control lymphocytes at concentrations of 1 x 10^ and
5 x 10^ cells per ml and preincubated as above prior to
cytotoxicity assay.
viii. Heat Treatment of Plasma.
Plasma samples were immersed in a u/ater bath at 56°C for 40
minutes to inactivate complement and will be referred to as heat
treated plasma (HTP). Fifty microlitres of HTP was then added
to 50 pi of control lymphocytes at concentrations of 1 x 10^ and
5 x 10^ cells per ml, the cells preincubated for 1 hour as before
prior to cytotoxicity assay.
ix. Monoclonal Antibody Labelling of Lymphocytes and Microscopy.
A lymphocyte suspension was taken from the whole blood sample
and washed 3 times in serum free medium (RPMI) prior to addition
of monoclonal antibody. One hundred microlitres of the optimum
/
dilution of the appropriate monoclonal antibody dilution was added
to 1 x 10^ lymphocytes for 20 minutes at room temperature. The
cells were washed 3 times in PBS and then 100 pi of the optimum
dilution of flourescein conjugated (goat antimouse IgG) added at
the appropriate dilution and incubated for a further 20 minutes at
room temperature. The cells were washed 3 times in PBS and re-
suspended in a small volume of saline,samples were kept in ice prior
to examination by flourescent microscopy on an ultraviolet microscope
(Leitz) for surface flourescence using water immersion at a magnification
of x 500. A total of between 150 and 200 cells were assessed for
monoclonal antibody staining in each sample.
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x. Raji Cell Assay for Detecting Immune Complexes.
This was based on the method of Theofilopoulos et al 1976. Test
and control sera (25 yl) which had previously been incubated for
30 minutes at 37°C with an equal volume of a 1 in 2 dilution of
fresh pooled normal human serum (as acompleinent source) were
added in triplicate to 2 x 10^ Raji cells in 70 x 12 mm polystyrene
tubes.
A reference standard curve was prepared in parallel by heat
aggregating (37°C for 30 minutes) Cohn fraction II, and adding
aliquots to the Raji cells to give a final concentration range of
1.5 yl to 400 yg/ml. Only normal control tubes that (a) were free
of both aggregate and serum, and (b) contained only normal human
serum were included in the assay. After incubating for 30 minutes
at 37°C,the cells were washed 3 times and then incubated for 45
minutes at 4°C with 80 yl of "^I-staphylococcal protein A which
had been iodinated with Iodogen, and used at an 'optimum dilution at
which saturated 1 gG bound to Raji cells. The cells were finally
washed 3 times and the radioactivity bound to the pellet counted and,
by reference to the standard curve the results expressed as yg/ml
equivalent of the aggregated Cohn fraction II.
xi. Total White Blood Cell Counts Morphological Studies of White Blood Cells.
Conventional microscopy using a Neubauer counting chamber and Giemsa
staining was performed to determine the total white blood cell count
of blood samples. In addition morphological studies of the white blood
cells were carried out to characterise the nature of the white cell




Plasma interferon lev/els were measured by the inhibition of cytopathic
effect method (Johnston 1981) as determined by uptake of a vital
dye. Confluent monolayers of the African Green Monkey kidney cell
line, V/3, in flat bottomed wells of microtest plates, were incubated
in the presence of serial dilutions of patients' plasma for 16 hours
prior to addition of the challenge virus, Semliki forest virus. The
diluent was medium 199 containing 2% foetal calf serum and all
incubations were carried out at 37°C in a humidified 5% CO^ in air
atmosphere. Cells surviving a 48 hour challenge period were stained
with 0.025% (w/v) crystal violet in 5% (V/v) formaldehyde. After
90 minutes at 37°C, the test plates were washed with distilled water
and the 50% protection end points determined by inspection. All
interferon titres are given in log .gIU/ml. A laboratory reference
human interferon standard, which had been calibrated against the
International Reference Preparation 69/19, was included as a positive
control.
xiii. In Vitro Incubation of PBL's with Exogenous Interferon.
Lymphocytes were separated from heparinized peripheral venous blood
by Ficoll-Hypaque density gradient centrifugation, washed in RPMI
3 times, counted and resuspended at a concentration of 10^ cells per
ml. Half of the cells were used in a 4 hour cytotoxicity assay
similar to the assay described for whole blood, at effector to target
ratios of 50, 25 and 12.5 to 1. The remaining cells were incubated
for 18 hours in a humidified CO2 atmosphere in the presence of 100 IU
of human leucocyte interferon per 10^ cells. These cells were then






Experimental results relating to the tumour effect on natural killer
lymphocytes.
4.1 Introduction
4.2 Cytotoxicity of peripheral venous blood of patients u/ith cancer
and benign disease against K362 target cells.
4.3 Natural cytotoxicity of arterial blood supplying the tumour and
venous blood draining the tumour during surgical operation.
4.4 Natural cytotoxicity of arterial blood supplying the gut and of
venous blood draining the stomach and colon in benign patients
during surgical procedure.
4.3 The effect of autologous plasma from benign controls on natural
cytotoxicity of peripheral blood lymphocytes.
4.6 The effect of plasma from patients u/ith cancer on K562 target cells.
4.7 The influence of plasma from cancer patients on natural cytotoxicity
to K362 targets by lymphocytes from benign controls.
4.8 The effect of plasma from patients with benign abdominal disease
on natural cytotoxicity to K562 targets by lymphocytes from
normal controls.
4.9 The effect of heat treatment of plasma from patients with benign
disease on natural cytotoxicity of PBL's from normal controls.
4.10 The effect of heat treatment of plasma from patients with malignant
disease on natural cytotoxicity of PBL's from normal controls.
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4.11 Assay for immune complexes in peripheral venous and tumour
draining venous blood.
4.12 Studies of white blood cell counts by morphology across the
tumour circulation.
a. total white blood cell counts.
b. total lymphocyte counts.
c. polymorphonuclear leucocyte counts.
4.13 Studies using the monoclonal antibody Leu 7 on lymphocytes




In view of the findings of several workers that natural killer cell
activity was reduced in patients with cancer (Pross and Baines 1976,
Kadish et al 1981) and particularly that natural killer cell activity
in the host was related to tumour burden (Pross and Baines 1976,
Horowitz et al 1983), the experiments described in this chapter were
undertaken to determine the influence of the tumour on NK activity of
the host and also to study the effect of passage through the tumour
circulation on the capacity of host natural killer lymphocytes to kill
tumour target cells (K562). Further studies were undertaken to
determine changes in lymphocyte subpopulations, particularly the natural
killer lymphocyte fraction, in the blood across the tumour circulation.
In addition the plasma taken from the peripheral venous, aortic,tumour
venous, stomach and colon venous blood of patients with cancer and
similar blood samples including tumour venous blood from patients with
benign abdominal disease was added to PBL's from healthy controls to
determine their influence on the natural cytotoxicity of control PBL's
to tumour target cells. This was undertaken to determine whether
factors present in the efferent venous blood from tumours were inhibitory
to exogenous NK cells taken from normal individuals.
4.2 Cytotoxicity of peripheral venous blood of patients with cancer
and benign disease against K562 target cells.
Cytotoxicity of peripheral venous blood to K562 target cells was
determined by the whole blood assay described in the materials and
methods section. Nineteen patients with benign abdominal disease and
27 patients with gastrointestinal cancer were studied. Of the 27 patients
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with cancer, 18 patients had localised primary tumours confined to
the organ of origin, i.e. either stomach or colon, and 8 patients
had disseminated disease with distant metastases. Blood samples were
taken from each patient prior to anaesthesia and surgery and the blood
tested at dilutions of 1/2, 1/4 and 1/8 for natural cytotoxicity.
Patient details and results expressed as percentage cytotoxicity are
shown in Table I.
The groups were not matched for age and sex. The patients with
malignant disease were older than those with benign disease (p<0.01
by Students "t" test), however this was not thought to influence NK
status significantly since this is known not to be age related in the
adult human (Takasugi et al 1973). In addition,regression analysis
of percentage cytotoxicity of peripheral venous blood versus age in
years of 18 patients with benign disease (r = 0.09) and 27 patients
with malignant disease (r = -0.012) failed to show any statistically
significant correlation of NK status with age. (Fig.'l.)
There was no significant difference in the mean cytotoxicity of the
patients with localised primary tumours compared to the patients with
benign abdominal disease at either dilution studied (Table I). There
was however, a significant reduction of the mean cytotoxicity at 1/2
and 1/4 dilutions (p<0.005 by Students "t" test) for patients with
disseminated malignant disease when compared to the benign controls.
This finding implies that NK lymphocyte mediated cytotoxicity of
peripheral venous blood against K562 target cells is directly






n = 19 7 M 12 F
Mean age - SEM 53.2 - 3.7 years
ii) Local malignant disease
n = 19 12 M 7 F
Mean age — SEM 66.6 — 3.0 years
iii) Disseminated malignant disease
n = 8 8 M 0 F
Mean age - SEM 66.7 - 2.45 years
MEAN PERCENTAGE CYTOTOXICITY ± SEM OF PERIPHERAL
VENOUS BLOOD TO K562 TARGETS
Dilution of Local malignant Disseminated
whole blood Benign disease malignant disease
1/2 16.3 ±2.7 11.2 ± 1.5 7.0 — 1.3*
V4 9.3 ± 1.15 7.5 ± 1.38 4.1 — 1.11*
1/8 5.5 ±0.75 4.15 ±0.89 2.9 ± 0.76
*
p< 0.005
4 hr, chromium release assay of peripheral venous whole blood against K562 targets.
V2 dilution with RPMI.
Statistical analysis by Student's "t" test.
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FIGURE 1
THE FAILURE OF CORRELATION BETWEEN CYTOTOXICITY OF
PERIPHERAL VENOUS BLOOD TO K562 TARGET CELLS AND AGE IN PATIENTS
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4 hr. chromium release assay against K562 targets using peripheral venous whole
blood at "V2 dilution.
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A .3 Natural cytotoxicity of arterial blood supplying the tumour
during surgical operation.
In 22 patients with histologically proven malignant disease of the
gastrointestinal tract, it was possible to sample aortic blood,
representing the arterial blood supplying the tumour, and venous blood
directly draining the tumour to assess natural cytotoxicity against
K562 targets. In 16 of these patients the tumour was an adenocarcinoma
of the large bowel, A patients had an adenocarcinoma of the stomach and
in the remaining 2 patients the tumour was a gastric lymphoma. The
results of the whole blood assay for natural killer cell activity in
the aortic blood and tumour venous blood against K562 targets are shown
in Table II a (1/2 dilution of the whole blood with RPMI) and Table II b
(1/A dilution with RPMI). Since each test is performed in triplicate
the results are expressed as mean percentage cytotoxicity ± one
standard deviation which enables statistical analysis by the paired
"t" test of the cytotoxicity of whole blood entering the tumour (aortic
blood) compared to the cytotoxicity in the tumour venous draining blood.
At the 1/2 dilution studied (Table Ila), A patients (JC, FW, WD and BR)
had statistically significant (p<0.05-p<0.01) depression of cytotoxicity
of blood after passage through the tumour circulation. In 3 of these
patients (JC, FW, WD) the tumour was an adenocarcinoma of the colon and
the remaining patient (BR) had an adenocarcinoma of the stomach. Three
patients (JB, PW and WN) had significant elevation (p<0.05-p<0.001) of
cytotoxicity in the tumour draining venous blood compared to the
aortic blood entering the tumour circulation. The tumours in these
3 patients were an adenocarcinoma of the colon (JB), lymphoma of stomach
(PW) and an adenocarcinoma of stomach (WN) respectively.
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TABLE 11A
PERCENTAGE CYTOTOXICITY ±SD OF WHOLE BLOOD TO K562
TARGETS ENTERING AND LEAVING THE TUMOUR CIRCULATION
1/2 DILUTION OF WHOLE BLOOD
Patient Tumour Aortic Tumour venous P value
JC Colon 23.5 + 5.4 6.8 ±2.2 <0.01
RR Colon 14.3 ± 4.3 16.4 ±3.4 NS
FO Colon 13.0 ± 1.0 10.5 ±2.6 NS
GW Colon 7.0 ± 1.5 6.5 ±0.6 NS
DG Colon 14.9 ± 3.1 11.4 ±0.36 NS
JB Colon 14.6 ± 0.7 20.3 ±3.3 < 0.001
WW Colon 15.8 ± 1.5 23.3 ±7.1 NS
FW Colon 43.1 ± 14.4 18.4± 1.7 <0.05
NF Colon 10.9 ± 1.5 10.7 ±3.4 NS
GH Colon 7.6 + 3.8 3.4 ±0.5 NS
WD Colon 18.6 ± 1.4 11.0 ± 2.9 <0.01
DP Colon 29.2 + 8.6 13.9 ±3.4 NS
MS Colon 5.2 ± 2.4 3.9 + 2.6 NS
NW Colon 16.9 ± 2.5 15.7 ± 4.4 NS
AH Colon 3.4 + 1.9 5.0 ±3.0 NS
AP Colon 3.6 ± 1.8 2.5 ±3.1 NS
PW Stomach 29.5 ± 3.7 35.0 ±2.6 < 0.01
JC Stomach 25.0 + 1.7 18.8 ±3.3 NS
WN Stomach 7.6 ± 1.3 18.8 ±5.4 <0.05
FP Stomach 2.9 ± 2.2 10.5 ±2.6 NS
BR Stomach 37.7 ± 6.2 26.7 ±5.4 <0.01
HW Stomach 4.6 ± 3.0 7.5 ±2.5 NS
4 hr. chromium release cytotoxicity assay for whole blood against K562 targets.
Statistical analysis by paired "t" test.
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table i ib
Percentage cytotoxicity ± so of whole blood to K562
targets entering and leaving the tumour circulation
% dilution of whole blood
Pt. Tumour Aortic Tumour venous p value
JC Colon 19.2 ± 2.7 4.5 ± 1.4 <0.001 i
RR Colon 9.7 + 0.5 13.5 + 0.7 0.01 t
FO Colon 6.5 ± 1.5 5.5 + 1.5 NS
GW Colon 3.5 + 1.4 4.9 + 0.8 NS
DG Colon 11.4 + 3.9 6.5 + 2.2 <0.05 4-
JB Colon 8.5 + 0.8 16.9 + 2.2 <0.01 t
WW Colon 8.2 + 3.3 11.8 + 4.1 NS
FW Colon 21.4 + 3.0 16.7 + 9.8 NS
NF Colon 18.9 + 1.5 21.3 ± 1.4 NS
GM Colon 7.7 + 6.0 2.7 + 1.6 NS
WD Colon 19.1 + 2.7 7.8 + 1.8 <0.02 4
DP Colon 15.2 + 4.2 0.5 + 0.5 <0.01 1
MS Colon 0.9 + 0.8 2.0 + 1.9 NS
NW Colon 11.8 + 2.1 12.2 + 2.2 NS
AM Colon 0.9 + 0.9 3.6 + 3.1 NS
AP Colon 0.0 + 0.3 2.6 + 0.8 NS
V
PW Stomach 23.2 + 5.3 30.0 + 4.3 NS
JC Stomach 10.5 + 10.0 3.8 + 1.6 NS
WN Stomach 6.5 + 1.0 17.7 + 3.1 <0.01 t
FP Stomach 1.5 + 0.7 3.7 + 2.7 NS
BR Stomach 33.0 + 1.1 26.9 + 3.1 <0.05 i
HW Stomach 3.5 + 1.6 5.3 + 1.6 NS
4 hr. chromium release cytotoxicity for whole blood against K562 targets.
Statistical analysis by paired "t" test.
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In the remaining 15 patients (12 colon tumours, 3 stomach tumours)
there was no significant change in cytotoxicity of whole blood after
passage through the tumour circulation.
At the 1/4 dilution studied, (Table lib) 5 patients (JC, DG, WD, DP
and BR) showed significant depression (p<0.05-p<0.001) of cytotoxicity
of whole blood in the tumour draining venous blood compared to the
aortic blood supplying the tumour. Four of these patients (JC, DG,
WD and DP) had an adenocarcinoma of the large bowel and the remaining
patient (BR) an adenocarcinoma of the stomach. In 3 patients (RB, JB,
and WN) there was significant elevation (p<0.05-p<0.01) of cytotoxicity
in the tumour draining venous blood compared to the aortic blood
supplying the tumour. The tumours in these patients were an
adenocarcinoma of the colon in 2 patients (RB, JB) and an adenocarcinoma
of the stomach in the remaining patient (WN) At this dilution there
were 14 patients (10 colon tumours, 4 stomach tumours) in whom there was
a statistically insignificant change in cytotoxicity in the aortic
blood compared to the tumour draining venous blood.
Analysis of the mean cytotoxicity by the paired "t" test for the aortic
and tumour venous blood at the 1/2 and 1/4 dilutions for all tumours
is shown in Figure 2. The mean percentage cytotoxicity ± SEM for the
aortic blood at the 1/2 dilution was 15.8 ± 2.4% which did not differ
significantly from the mean percentage cytotoxicity ± SEM for the
tumour draining venous blood at 13.2 ± l.R2%. Similarly at the
1/4 dilution studied, there was no significant difference in the mean
percentage cytotoxicity ± SEM of the aortic blood at 11.4 ± 1.85%
compared to that of the tumour draining venous blood at 10.4 ± 1.83%.
These data suggest that in the majority of patients with gastrointestinal
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' FIGURE 2
CYTOTOXICITY OF WHOLE BLOOD TO K562 TARGETS OF AORTIC BLOOD
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4 hr. chromium release assay.
Results are the mean of 3 separate tests for each patient.
Statistical analysis by the paired "t" test.
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tumours, there is no significant depression or elevation of natural
cytotoxicity of u/hole blood to K562 tumour target cells after passage
through the tumour circulation. There is however a degree of individual
patient variation with, in some patients, depression of natural
cytotoxicity of whole blood after passage through the tumour whilst in
other patients there appears to be an enhancement of natural cytotoxicity.
In these patients, there may be factors active in the tumour circulation
which could result in either depression or enhancement of host natural
cytotoxicity.
4.4 Natural cytotoxicity of arterial blood supplying the gut and
of venous blood draining the stomach and colon in benign patients
during surgical operation.
In order to ascertain whether there existed a gradient of natural killer
cell activity across the stomach and colon of patients without gastro¬
intestinal tumours, blood samples were taken during-operation on 10
patients with benign upper abdominal conditions. Five of these patients
were undergoing cholecystectomy for gallstones, 3 patients had surgery
for duodenal ulcer disease and the remaining 2 patients partial gastrectomy
for benign gastric ulcer. Blood was taken from the aorta and also
veins draining the stomach and colon, diluted with RPMI to 1/2 and 1/4
dilution and then estimation of natural cytotoxicity against K562 target
cells was performed. The results are expressed as percentage
cytotoxicity ± SD and shown in Table III.
There was some variation between patients in the natural cytotoxicity
of arterial blood supplying the gut and venous blood draining the stomach
and colon.
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At the 1/2 dilution studied, in 2 patients (GK, EB) there was
significant (p<0.01,p<0.001) depression of natural cytotoxicity to
K562 targets in the stomach venous blood compared to the aortic blood
supplying the gut and in one patient (GB), natural cytotoxicity was
significantly (p<0.01) elevated in the stomach venous blood. Only
one patient (MG) showed any significant change in natural cytotoxicity
of the colon venous blood with a significant depression (p<0.01) of
cytotoxicity when compared to the aortic blood. In the remaining
patients there was no significant change of natural cytotoxicity of
blood draining the stomach and colon when compared to the aortic
blood.
At the 1/4 dilution studied, in one patient (NT) there was significant
depression (p<0.01) of stomach draining venous blood cytotoxicity
compared to the cytotoxicity of the aortic blood supplying the gut.
One patient (GK) showed depression (p<0.01) of cytotoxicity in the
blood draining the colon compared to aortic blood and a further
patient (PB) showed significant (p<0.01) elevation of natural cytotox¬
icity of blood draining the colon. All of the remaining patients failed
to show any significant change in natural cytotoxicity of blood
draining the stomach and colon circulations when compared to the natural
cytotoxicity of aortic blood supplying the gut.
In Table IV, the mean percentage cytotoxicities to K562 of the 3 tests
performed on the aortic, stomach venous and colon venous blood of each
patient at 1/2 and 1/4 dilutions with RPMI are shown. There is no
statistically significant difference between the mean ± SEM aortic
cytotoxicity at 25.0 ± 5.1?o and that of the stomach draining venous
blood at 25.1 ± 4.9?o and the colon draining venous blood at 21.7 ± 4.5?o
at the 1/2 dilution studied. Similarly at the 1/4 dilution, the
TABLE III
PERCENTAGE CYTOTOXICITY ±SD OF WHOLE BLOOD TO K562
TARGETS IN AORTIC BLOOD, STOMACH AND COLON VENOUS BLOOD
OF PATIENTS WITH BENIGN ABDOMINAL DISEASE
1/2 DILUTION
Patient Diagnosis Aortic Stomach venous P Colon venous P
MB Gallstones 11.1 ± 1.2 3.7 ±2.1 NS 9.4 ± 1.8 NS
NT Gallstones 59.3 ± 2.3 52.5 ± 1.6 NS 27.9 ±2.0 NS
GK D U 10.9 + 1.1 3.6 ±1.5 <0.011 9.3 ±2.7 NS
GB D U 9.8 ± 1.3 20.7 ± 3.4 <0.01t 11.8 ± 1.4 NS
EB Gallstones 34.8 ± 3.9 20.7 ±2.5 <0.00H NT
MG Gallstones 20.5 ± 2.1 17.6 ±0.2 NS 10.4 ±0.9 <0.01 ^
WW D U 32.0 ±3.7 26.4 ± 0.9 NS 36.7 ± 5.9 NS
PB Gallstones 33.0 ±1.2 44.0 ± 7.7 NS 36.9 ±7.2 NS
MT G U 10.5 ±2.2 14.5 ± 1.2 NS 13.2 ± 1.2 NS
FA G U 8.0 ±2.1 11.0± 8.5 NS 8.2 ± 1.1 NS
1/4 DILUTION
Patient Diagnosis Aortic Stomach venous Colon venous
MB Gallstones 9.3 ± 2.3 12.0 ±7.5 NS 8.5 ±2.0 NS
NT Gallstones 9.2 ± 2.0 0.1 ±0.05 <o.on 8.4 ±2.5 NS
GK D U 25.8 ± 2.2 33.9 ±5.2 NS 17.2 ±3.6 <0.01 i
GB D U 8.2 ± 2.9 11.7 ± 2.7 NS 6.8 ±1.5 NS
EB Gallstones 22.4 ±3.5 15.9 ±7.5 NS NT
MG Gallstones 12.7 ±4.6 8.5 ± 1.4 NS 8.8 ± 0.6 NS
WW D U 12.4 ±2.7 19.2 ± 2.0 NS 29.6 ±0.8 NS
PB Gallstones 20.3 ± 2.0 25.5 ± 8.4 NS 26.7 ± 0.9 <0.01 T
MT G U 7.4 ±3.5 9.4 ± 1.8 NS 9.3 ±1.9 NS
FA G U 11.5 ± 1.3 9.0 ± 3.6 NS 4.2 + 3.6 NS
4 hr. chromium release cytotoxicity assay.
Statistical analysis by paired "X" test.
NS = not significant NT = not tested
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TABLE IV
PERCENTAGE CYTOTOXICITY OF AORTIC BLOOD,
STOMACH AND COLON DRAINING VENOUS BLOOD














Mean 25.0 25.1 21.7
-S.E.M. ±5.1 ±4.9 ±4.5
4 NS >













Mean 13.9 13.2 11.3
±S.E.M. ±2.0 ±3.3 ±3.2
4 NS *
P value < NS »
4 hr. chromium release assay of whole blood against K562 targets.
A = aortic SV = Stomach venous CV = Colon venous
Individual patients percentage cytotoxicity expressed as a mean of 3 tests.
Statistical analysis by paired "t" test.
78.
differences in the mean ± SEM aortic cytotoxicity at 13.9 ± 2.0%
and the stomach venous at 13.2 + 3.3% and the colon venous at
11.1 ± 3.2% are not statistically significant.
The results of these experiments suggest that there is no consistent
effect with either marked elevation or depression of natural killer
lymphocyte activity after passage through the circulation of stomach
and colon in patients u/ith non malignant disease.
4.3 The effect of autologous plasma from benign controls on natural
cytotoxicity of peripheral blood lymphocytes.
These experiments were undertaken to determine whether autologous plasma
from laboratory staff whose lymphocytes were used as benign controls
in the experiments described later in this chapter, had either a
stimulating or inhibitory effect on the cytotoxicity of these lymphocytes.
Lymphocytes were separated from the peripheral venous blood of 8 control
subjects as described in the materials and methods section. A
lymphocyte suspension in RPMI was prepared at a concentration of 1 x 10^
cells/ml and 0.3 x 10^ cells/ml to give effector to target ratios of 50 and
25 to 1 respectively.
fifty microlitres of the lymphocyte suspension was incubated with 50pL of
autologous plasma for 1 hour at 37°C prior to use in a cytotoxicity assay
against K562 target cells. The results are shown in Table V.
There was no statistically significant difference between the mean ± SEM
cytotoxicity of the lymphocytes incubated in RPMI (38.6 ± 3.7% and 23.7 ±
3.0%) compared to those incubated with autologous plasma (36.3 ± 4.9% and
20.3 ± 4.2%) at effector to target ratios of 50:1 and 25:1 respectively.
This experiment showed that incubation of the lymphocytes with autologous
plasma did not enhance or depress cytotoxicity to K562 target cells.
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TABLE V
THE EFFECT OF THE ADDITION OF AUTOLOGOUS PLASMA TO
PBL'S ON PERCENTAGE CYTOTOXICITY TO K562 TARGET CELLS
Effector : target ratio 50 : 1
n = 8























Effector : target ratio 25 : 1























4 hr. chromium release cytotoxicity release assay
Statistical analysis by the paired "t" test.
NS = not significant
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4.6 The effect of plasma from patients u/ith cancer on K562 target cells.
In these experiments, the effect of incubation of K562 tumour target
cells with plasma from the peripheral venous blood, aortic and tumour
draining venous blood from 11 patients with gastrointestinal cancer was
studied to establish whether the plasma alone from patients with cancer
had any cytotoxic effect against K562 tumour target cells. One hundred
microlitres of the plasma from either the peripheral venous blood, aortic
blood or venous blood draining the tumour was added to 100 yL of K562
target cells at a concentration of 1 x 10^ cells/ml which had previously
been labelled with "'"Cr. The test plates were incubated for 4 hours at
37°C prior to estimation of radioactivity of the supernatant. The results
are expressed as percentage ''"tr release (see materials and methods
section) and are shown in Table VI.
The percentage r release following incubation of the K562 tumour cells
with plasma from the cancer patients was not significantly different
from the spontaneous release of the K562 cells incubated in RPMI (i.e.
target control). This indicates that the plasma from the cancer patients
and particularly the plasma from the venous blood draining the tumour
does not have any significant cytotoxic effect on K562 tumour cells.
4.7 The influence of plasma from cancer patients on natural
cytotoxicity to K562 targets by lymphocytes from benign controls.
Blood samples were taken during surgery from patients with gastrointestinal
tumours as follows:
i. Peripheral Venous blood,
ii. Aortic blood,
iii. Tumour draining venous blood.
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TABLE VJ
THE EFFECT OF PLASMA ALONE FROM CANCER PATIENTS ON
K562 TARGET CELLS ON RELEASE OF 51Cr. COMPARED TO
SPONTANEOUS RELEASE FROM TARGET CELLS
Patient Target control K562 + K562 + K562
(i.e. K562 + media) PV plasma A plasma + TV pla:
JC 14.9 13.4 15.6 14.9
PW 5.9 9.8 7.6 10.7
RR 13.6 10.0 9.0 13.2
GW 3.5 5.1 7.1 6.0
DG 13.4 14.9 12.3 14.1
JB 14.4 14.5 13.4 15.0
FW 13.8 12.8 13.8 12.4
BR 9.1 10.0 12.3 13.9
MS 6.3 7.4 10.1 7.4
AM 9.3 9.6 8.7 11.7
HW 15.2 15.1 14.3 13.8
Mean 10.8 11.1 11.2 12.1
±S.E.M. -1.26 ±0.98 ±0.87 ±0.9
PV = peripheral venous A = aortic TV = tumour venous
Spontaneous release of ^Cr after 4 hrs. Individual results are the mean of 3 tests.
The differences between the mean release of 51cr.are not statistically significant for
K562 incubated in PV, A, TV plasma compared to control.
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iv. Blood from a vein draining macroscopically normal tissue 15 cm
or more distant to the tumour.
Plasma was separated from these samples and stored at -80°C prior to
use. Peripheral blood lymphocytes from normal controls were separated
and incubated for 1 hour with these plasma samples as described in the
materials and methods section. A 4 hour•cytotoxicity assay was then
performed using these lymphocytes aginst K562 target cells.
In figures 3 & 4, results of incubation of PBL1s from normal healthy
controls with peripheral and tumour draining venous plasma from cancer
patients is shown at effector to target ratios of 50 and 25 to 1. For
these experiments the control PBL's were incubated in RPMI with no
added plasma.
Plasma from 19 patients was available for study at the effector to
target ratio of 50:1. After incubation with the peripheral venous plasma
from the cancer patients, there was a reduction in the mean ± SEM
percentage cytotoxicity from 40.1 ± 2.0 to 34.3 ± 2.2 which was significant
by the paired "t" test (p<0.02). Incubation of the control PBL's with
the tumour venous plasma resulted in a profound depression of mean ± SEM
percentage cytotoxicity from 40.1 ± 2.0 to 22.5 ± 2.81 which was highly
significant by the paired "t" test (p<0.001).
The experiment was repeated at an effector to target ratio of 25:1 and
plasma from 18 patients with cancer was available for study. Incubation
of the control PBL's with the peripheral venous plasma resulted in a
slight reduction in mean ± SEM percentage cytotoxicity from 23.1 ± 2.1 to
21.1 ± 2.6 which was not statistically significant. Incubation of the control
PBL's with the tumour venous plasma, however, caused a profound depression
in mean ± SEM percentage cytotoxicity from 23.1 ± 2.2 to 10.5 ± 1.9 which
again was highly significant by the paired "t" test (p<0.001).
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FIGURE 3
THE INFLUENCE OF PLASMA F ROM PATIENTS WITH MALIGNANT
GASTROINTESTINAL TUMOURS ON NATURAL KILLING OF K562
TARGETS BY LYMPHOCYTES FROM BENIGN CONTROLS
EFFECT OR:TARGET 50:1




















±SEM ±2.0 p< 0.001 ±2.81
4 hr. chromium release assay against K562 targets.
Individual patient results are the mean of 3 separate tests
Statistical analysis is by the paired "t" test
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FIGURE 4
THE INFLUENCE OF PLASMA FROM PATIENTS WITH MALIGNANT
GASTROINTESTINAL TUMOURS ON NATURAL KILLING OF K562
TARGETS BY LYMPHOCYTES FROM BENIGN CONTROLS
EFFECTOR : TARGET 25 : 1
n =1 8
% Cytotoxicity















±SEM ±2.2 p< 0.001 ±1.9
4 hr. chromium release assay against K562 targets.
Individual patient results are the mean of 3 separate tests.
Statistical analysis is by the paired "t" test.
NS = not significant
These results could be interpreted as showing evidence for a tumour
factor or tumour associated factor which is in high concentration in the
tumour draining venous blood. This factor could depress NK activity of
normal lymphocytes but would be diluted by passage through the blood
circulation which would account for the reduced level of depression seen
after incubation with the peripheral venous blood of the cancer patients
studied.
The results of cytotoxicity to K562 after incubation of control PBL's with
plasma from the peripheral venous blood, aortic blood, tumour draining
venous blood and either stomach or colon venous blood from macroscopically
normal adjacent tissue are shown in Table VII with the means expressed
graphically in Figure 5. Several different patterns emerge from the
data expressed in Table VII and could be explained as follows:
i. The tumour associated factor responsible for depression of natural
killer activity of lymphocytes is in high concentration in the
tumour draining venous blood but subsequent dilution of the factor
in the circulating blood results in a lower concentration in the
peripheral venous blood, aortic blood and blood draining
macroscopically normal adjacent tissue, for example patients JC,
JB, FP.
ii. In some patients, for example FO, NF, DG, there are high circulating
levels of this factor with a generalised reduction of cytotoxicity
of control PBL's after incubation with plasma from the peripheral
venous,aortic, tumour venous and blood draining adjacent normal tissue,
iii. In some patients, e.g. WD, FW, WW the blood draining macroscopically
normal tissue adjacent to the tumour appears also to depress NK
activity from normal controls.
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TABLE VII
THE EFFECT OF PLASMA FROM CANCER PATIENTS ON NATURAL
CYTOTOXICITY OF PBL'S FROM NORMAL CONTROLS
% Cytotoxicity
Patient Control + PV + A + TV + CV
(colon tumours)
JC 51.0 53.0 46.9 18.7 44.6
RR 51.0 42.9 43.0 34.5 29.6
GW 32.7 30.0 15.6 20.2 NT
FO 38.5 24.0 24.1 23.5 21.6
DG 38.5 20.0 20.6 1.8 9.7
JB 49.3 52.9 45.3 19.8 40.0
WW 41.6 34.9 44.0 18.3 8.5
FW 44.1 35.4 25.1 1.9 1.0
NF 44.1 27.7 29.7 29.3 27.0
WD 23.2 33.9 34.9 10.3 2.9
DP 32.0 29.0 36.0 34.9 8.6
MS 50.0 49.6 41.2 44.6 48.5
AH 28.6 39.0 40.0 23.5 30.0
NW 51.6 28.4 34.2 36.2 31.2
GP 51.6 27.3 22.4 19.1 28.4
(stomach tumours) Control + PV + A + TV + SV
WN 32.7 36.2 39.8 36.6 31.9
PW 38.5 38.1 31.2 29.7 32.3
FP 30.7 18.5 17.3 3.0 17.2
BR 32.3 31.1 21.1 21.9 0.3
Mean cytotoxicity 40.1 34.8 32.2 21.2 22.9











PV = peripheral venous A = aortic TV = tumour venous
CV = colon venous SV = stomach venous
4 hr. chromium release assay against K562 targets.
Results expressed for individual patients are the mean of 3 experiments.
Effector : target ratio 50 : 1














* p < 0.02




I I I I I
PBL's PBL's PBL's PBL's PBL's
+ RPMI +PV +A +TV +S/CV
PV = PERIPHERAL VENOUS PLASMA
A = AORTIC PLASMA
TV = TUMOUR VF.NOUS PLASMA
S/CV = STOMACH/COLON VENOUS PLASMA
4 hr. chromium release assay against K562 targets.
Effector to target ratio 50 : 1. Statistical analysis by paired "t" test with control PBL's in RPMI.
This could be explained by the tumour factor remaining at high
concentration in the venous blood draining the adjacent tissue due
perhaps to a particularly rich collateral venous drainage.
In patients, BR and DP, the plasma from the tissue adjacent to the
tumour w as more inhibitory to NK activity of control lymphocytes than
the tumour draining venous blood, the reason for this effect is unknown.
Statistical analysis by the paired "t" test of the mean cytotoxicity of
the control PBL's after incubation in the peripheral venous.aortic,
tumour venous and venous blood draining adjacent tissue (stomach or
colon) when compared to the control PBL's incubated in RPMI showed a
significant reduction (p<0.02 - p<0.001) for all plasma samples. The
most significant reduction was observed with the mean cytotoxicity
after incubation with tumour venous plasma (p<0.001) and plasma from
the venous blood draining adjacent tissue (p<0.001). These data confirm
the inhibitory nature of plasma from patients with malignant gastro¬
intestinal tumours which is most marked in the plasma from venous
blood draining the tumour and tissue adjacent to the tumour.
A.8 The effect of plasma from patients with benign abdominal disease
on natural killing of K562 targets by lymphocytes from normal
controls.
This experiment was undertaken to establish whether the stomach or colon
per se in patients with non malignant disease could produce factors which
might be inhibitory to natural cytotoxicity of lymphocytes.
In 6 patients with benign upper abdominal conditions undergoing routine
surgical procedures, plasma was separated from the aortic blood, venous
blood draining the stomach and venous blood draining the colon. Fifty
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microlitres of PBL's from normal subjects of a concentration of
1 x 10^ cells/ml and 0.5 x 10^ cells/ml were incubated u/ith 50yL of
plasma for 1 hour at 37°C prior to use in a A hour cytotoxicity assay
against K562 target cells at an effector to target ratio of 50:1 and
25:1. The patient details and results of the cytotoxicity assays
are shown in Table VIII.
At the 50:1 effector to target ratio studied, the plasma from the
aortic, stomach venous and colon venous blood of 3 patients (WW, PB,
MB) failed to inhibit natural killing by control PBL's. Plasma from
the stomach draining venous blood of 2 patients with histologically
benign gastric ulcer (FA, MT) did however depress natural cytotoxicity
of the control PBL's and plasma from the stomach and colon draining
venous blood of one patient (HB) caused depression of natural cytotoxicity.
The difference in the mean ± SEM percentage cytotoxicity of the control
PBL's at 35.3 ± "1.1% and the PBL's incubated in aortic plasma at 33.8 ±
6.3 was not significant. The mean± SEM cytotoxicites of the PBL's
incubated in stomach venous plasma (20.5 ± 1.9%) and colon venous plasma
(27.8 ± 7.5%) was signficantly reduced (p<0.05 and p<0.02) when compared
to the control PBL's at this effector to target ratio.
At the 25:1 effector to target ratio, the plasma from the stomach draining
venous blood of one patient with a gastric ulcer (MT) caused depression
of natural cytotoxicity of the control PBL's to K562 targets as did
plasma from the colon venous blood of patient HB.
The difference in the mean ± SEM cytotoxicities of the PBL's incubated
in aortic plasma (18.3 ± 3.5%), stomach venous plasma (14.3 ± 4.6%)
and colon venous plasma (16.3 ± 4.3%) did not reach statistical significance
when compared to the mean ± SEM percentage cytotoxicity of the control
PBL's (18.7 ± 3.0%).
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TABLE VIII
THE EFFECT OF PLASMA FROM PATIENTS WITH BENIGN DISEASE
ON PERCENTAGE CYTOTOXICITY OF PBL'S FROM NORMAL CONTROLS
TO K562 TARGET CELLS
Effector : Target ratio 50 : 1
p value
% cytotoxicity % cytotoxicity of PBL's
+ plasma
Patient Diagnosis Control PBL's A SV CV
WW D U 24.3 22.2 24.1 20.4
PB Gallstones 24.3 22.2 15.5 21.1
MB Gallstones 55.0 57.0 57.0 55.0
FA G U 55.0 49.2 18.3 38.0
MT G U 40.0 31.4 5.7 32.0
HB Gallstones 13.2 20.9 2.5 0.7
Mean 35.3 33.8 20.5 27.8




Effector : target ratio 25 : 1
% cytotoxicity % cytotoxicity of PBL's
+ plasma
Patient Diagnosis Control PBL's A SV CV
WW D U 14.4 11.8 13.4 14.2
PB Gallstones 14.4 13.2 9.9 12.7
MB Gallstones 27.0 32.0 33.8 33.3
FA G U 27.0 25.9 19.7 17.3
MT G U 20.6 19.4 9.3 19.8
HB Gallstones 9.0 10.1 — 0.6
Mean 18.7 18.3 14.3 16.3
±S.E.M. ±3.0 ±3.5 ±4.6 ±4.3
NS




4 hr. chromium release assay against K562 targets.
Individual patient results are the mean of 3 experiments.
A = aortic plasma SV = stomach venous plasma CV = colon venous plasma
Statistical analysis by the paired "t" test
NS = not significant
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The depression of natural cytotoxicity seen when control PBL's were
incubated in the stomach venous plasma of 2 patients with benign
gastric ulcers is of interest since although these ulcers were
histologically benign, they could in some way be responsible for the
production of a factor by inflammatory cells reacting to the ulcer
which could depress NK activity. In patient HB, the stomach and
colon venous plasma was inhibitory to NK activity of the PBL's at the
effector to target ratios of 50:1, no explanation can be put forward
for this effect.
Taking the results overall, apart from the patients with gastric ulcers,
it would appear that normal stomach and colon in patients with benign
gastrointestinal disease, do not consistently produce factors which
result in depression of natural killer cell activity by PBL's from
normal controls. The number of patients studied however, was small and
more patients should be studied in future to determine this with certainty.
4.9 The effect of heat treatment of plasma from patients with benign
disease on natural cytotoxicity of PBL's from normal controls.
Plasma from 5 patients with benign abdominal disease (cholelithiasis) was
heated at 56°C for 40 minutes and incubated with PBL's from normal
controls prior to cytotoxicity assay against K562 targets. This was
compared to the cytotoxicity of PBL's incubated with non heat treated
plasma from the same patients (Table IX). This was a statistically
significant (p<0.005) fall in mean ± SEM percentage cytotoxicity from
17.3 ± 1.25?d after incubation with the non heated plasma to 11.6 ± 2.0%
for the PBL's incubated with heat treated plasma indicating that heat
treatment of the plasma had altered the plasma to cause depression of NK




THE EFFECT OF HEAT TREATMENT OF PLASMA FROM BENIGN
CONTROLS ON PERCENTAGE CYTOTOXICITY OF PBL'S FROM
BENIGN CONTROLS
Effector : target ratio 25 : 1
























NS 17.3 p< 0.005 11.6
> 4 >
±1.25 p < 0.005 ±2.0
>
4 hr. chromium release assay against K562 targets.
Individual results are the mean of 3 experiments.
Statistical analysis by the paired "t" test.
NS = not significant.
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4.10 The effect of heat treatment of plasma from patients with
malignant disease on natural cytotoxicity of PBL's from
normal controls.
Previous experiments had shown that the cytotoxicity of PBL's from
normal controls was reduced after incubation with plasma from the
peripheral venous blood of patients with cancer and the cytotoxicity
of these lymphocytes was profoundly reduced after incubation with
the plasma from the venous blood draining the tumour.
This could suggest the presence of a tumour factor or tumour associated
factor in high concentration in the tumour venous blood. In this
experiment, the effect of heat inactivation of plasma from the cancer
patients was assessed. Plasma was heated at 36°C for 40 minutes to
determine whether the factor responsible for depression of NK activity
of control PBL's was heat stable.
Heat treatment of plasma from the peripheral venous^and tumour venous
blood of 9 patients with gastrointestinal cancer resulted in profound
depression of natural killing of control lymphocytes (11.4 ± 3.9?o and
9.8 ± 3.5?o) compared to the non heat inactivated plasma from the same
sites (31.8 ± 3.2% p<0.001 and 19.9 ± 4.7?o p<0.02) respectively.
(Figure 6).
These results suggest that the depressantfactor found in tumour draining
venous blood may be heat stable because if the factor were inactivated
by heat treatment of the plasma, either abrogation or a substantial
reduction in the depression of cytotoxicity of control lymphocytes




THE EFFECT OF HEAT TREATMENT OF PLASMA FROM CANCER PATIENTS ON CYTOTOXICITY
OF CONTROL PBL'S TO K562 TARGETS










* p < 0.02







4 hr. chromium release assay against K562 targets using PBL's from a healthy control.
Effector : target ratio 50 : 1
O = non heat treated plasma
A = heat treated plasma
Mean cytotoxicity for PBL's incubated in heat treated and non heat treated plasma obtained from 9 patients.
Statistical analysis is by paired "t" test.
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The reason for the depressed level of cytotoxicity of the control PBL's
seen after incubation with the heat treated plasma remains unknown but
may be related to precipitates of plasma proteins being formed which may
block NK activity of the control lymphocytes by inhibiting binding to
tumour target cells.
A.11 Assay for immune complexes in peripheral venous and tumour
draining venous blood.
Circulating immune complexes have been identified in cancer patients by
many workers and the levels of these complexes may be related to the
prognosis of these patients. These complexes are thought to result from
the shedding of tumour associated antigen which complexes with lgG or
lgM and therefore these complexes would be expected to be in high
concentration in the venous blood draining the tumour.
One suggested mechanism of depressed natural killer lymphocyte
cytotoxocity to tumour cells by tumours is the combination of the immuno¬
globulin associated with the immune complex with the F'c immunoglobulin
receptor on the NK lymphocyte which could result in reduced binding of
NK cells to tumour cells. Timonen and Saksela (1977) have demonstrated
that NK cell killing of target cells is reduced in the presence of
immune complexes of lgG and lgM.
The Raji cell assay is one of the most sensitive assays for circulating
immune complexes described for patients with colorectal tumours
(Hobbiss et al 1983). This assay was performed using the tumour venous
plasma from 11 cancer patients to detect possible presence of high levels
of circulating immune complexes.
96.
In Table X the results of Raji cell assays for immune complexes in the
plasma of peripheral and tumour venous blood of 11 patients are shown together
with their effect on NK cell cytotoxicity towards K562 targets. The
results are expressed as yg/ml of Cohn fraction II, values above 20 yg/
ml are regarded as positive for immune complexes.
None of the 11 patients studied showed evidence of levels of immune
complexes in the tumour venous or peripheral venous blood above the normal
level of laboratory controls. It remains possible that immune complexes
were present but not detected by the Raji cell assay. This, however, is
unlikely in view of the sensitivity of this assay in patients with cancer
found by other workers. These results would therefore suggest that
the depression in natural cytotoxicity of lymphocytes to K562 target
cells is not mediated by the presence of immune complexes.
4.12 Studies of white blood cell counts by morphology across the
tumour circulation.
These studies were undertaken to determine the total white blood cell
counts, polymorphonuclear leucocyte counts and total lymphocyte counts
in the arterial blood entering the tumour and the venous blood draining
the tumour.
a. Total white blood cell counts.
Aortic blood, representing arterial blood entering the tumour.and
the venous blood draining the tumour was prepared and stained as
described in the materials and methods section for microscopy.
The results for the total white blood cell counts were expressed
9
as cells X1D /L and are shown in figure 7 (a). Although 2 patients




RAJI CELL ASSAY FOR CIRCULATING IMMUNE COMPLEXES IN
TUMOUR VENOUS AND PERIPHERAL VENOUS BLOOD OF
PATIENTS WITH CANCER
TV plasma
Site of effect on cytotoxicity Raji cell assay Raji cell assay
Patient tumour on control PBL's TV plasma PV plasma
FP Stomach depressed 2.5 2.7
PW Stomach no change 2.2 1.5
JB Colon depressed 1.9 2.4
RR Colon depressed 1.6 1.6
FW Colon depressed 1.7 1.6
NW Colon depressed 4.1 4.9
AP Colon depressed 3.1 4.8
WN Stomach no change 3.2 3.4
DG Colon depressed 3.4 3.8
WD Colon depressed 4.4 4.2
BR Stomach depressed 5.5 4.2
Results are expressed in pg/ml
Values above 20 pg/ml are considered positive for immune complexes
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tumour circulation (i.e. aortic to tumour venous) the majority of
patients showed no significant change and the difference between
the mean ± SEM count for the aortic blood at 6 ± 0.72 cells X 109/L
g
and the mean ± SEM for the tumour venous blood at 5 ± 0.54 X 10 /L
was not statistically significant by the paired "t"test.
b. Total lymphocyte counts.
Total lymphocyte counts by microscopy were performed on aortic and
g
tumour draining venous blood and expressed as cell X 10 /L. The
results are shown in Figure 7 (b). Three patients showed considerable
variation of total lymphocyte counts across the tumour circulation,
one with elevated numbers in the tumour venous blood and two with
reduced numbers in the tumour venous blood when compared to the
aortic blood. The remaining patients did not show any marked difference
in total lymphocyte counts across the tumour circulation and this is
reflected in the lack of a statistically significant difference between
the mean ± SEM total lymphocyte count of the aortic blood at 3.05±
g
0.63 X 10 cells/ml and the mean ± SEM of the tumour venous blood at
2.91± 0.35X 109 cells/ml.
c. Polymorphonuclear leucocyte counts.
Polymorphonuclear leucocyte counts were performed on aortic and tumour
g
draining venous blood with counts expressed as cells X 10 /mt. The
results are shown in Figure 7 (c). Two patients showed considerable
reduction in polymorphonuclear leucocyte cell counts across the tumour
circulation and these 2 patients correspond to the 2 patients in
Figure 7 (a) who demonstrated a considerable reduction in total white
blood cell count across the tumour indicating that this fall was due
to a reduction in polymorphonuclear leucocyte numbers. This may
represent sequestration of these cells in the tumour at a site of
FIGURE7
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Statisticalanalysisbthep red"t"est. NS=notsignificant. CellcountsbymicroscopyafterGi m astaining
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bacterial inflammation. In 2 patients there was elevation of
polymorphonuclear leucocyte numbers across the tumour however the
majority of patients failed to show any appreciable change across
the tumour. The mean ± SEM aortic polymorphonuclear leucocyte
9
cell count at 3.55± 1.3 X 10 cells/ml was not significantly different
9
from the tumour venous count at 2.13± C.35X 10 cells/L but perhaps
suggests a net sequestration of polymorphonuclear leucocytes within
the tumour.
4.13 Studies using the monoclonal antibody Leu 7 on lymphocytes
traversing the tumour circulation.
A possible mechanism of depressed natural killer lymphocyte activity
of blood from patients with cancer is the sequestration of natural killer
lymphocytes within the tumour. Experiments were therefore performed to
identify NK lymphocyte populations across the tumour circulation using
the monoclonal antibody Leu 7. This antibody is a relatively specific
marker for the natural killer lymphocyte although there is some cross
reactivity with suppressor lymphocytes.
There were sufficient lymphocytes available from the aortic blood and
tumour draining venous blood of 9 patients with gastrointestinal tumours
for labelling with Leu 7 monoclonal antibody (Abo and Balch 1981s.
Lymphocytes were separated and labelled with the Leu 7 antibody using
an individual fluorescent technique as described in the materials and
methods section. Ultraviolet microscopy was performed to determine the
percentage of Leu 7 positive cells in each lymphocyte population.
The results (figure 8) show that there is some individual tumour variation
with a reduction in the percentage of Leu 7 positive cells after passage
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FIGURE 8
















Statistical analysis by the paired "t" test.




PERCENTAGE OF LEU 7 POSITIVE CELLS ACROSS THE TUMOUR
CIRCULATION COMPARED TO THE EFFECT OF PASSAGE THROUGH
THE TUMOUR CIRCULATION ON NK CYTOTOXICITY OF WHOLE BLOOD
Cytotoxicity to K562
after passage through
Patient Tumour Aortic Tumour venous the tumour circulation
FW Colon 33% 49% depressed
WW Colon 45% 43% elevated
MS Colon 5% 13% elevated
NF Colon 47% 43% no change
HW Stomach 27% 32% elevated
AH Colon 27.5% 22.2% elevated
AP Colon 28.3% 38.1% depressed
NW Colon 22.8% 31.1% no change
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through the tumour circulation in 4 patients and an elevated percentage
of Leu 7 positive cells in 5 patients. The difference between the
mean ± SEN percentage of Leu 7 positive cells in the aortic blood at
29.3 ± 4.1% and that of the tumour venous blood at 32.3 ± 4.07. was not
statistically signficant by the paired "t" test.
In Table XI, the percentage of natural killer lymphocytes as determined
by positive staining with Leu 7 monoclonal antibody in the arterial
blood entering the tumour circulation and the venous blood draining the
tumour with the net effect on the cytotoxicity of whole blood to K362
target cells after passage through the tumour circulation is shown in
8 patients. There appeared to be no correlation between reduced
percentage of Leu 7 positive cells and alteration in NK lymphocyte
cytotoxicity of whole blood after passage through the tumour circulation.
This observation would suggest that alteration of natural cytotoxicity
of whole blood after passage through the tumour is not related to changes
in NK lymphocyte numbers. In those tumours where depression of natural
cytotoxicity is observed in the tumour draining venous blood, this effect
is likely to be due to an effect on NK lymphcoytes, resulting in reduced
capacity for natural killing of tumour cells rather than depletion of
cell numbers.
4.14 Discussion.
From the results of the experiments described in this chapter, it would
appear that malignant tumours of the gastrointestinal tract have an
effect on the natural cytotoxicity to tumour cells mediated by the natural
killer lymphocytes of the host. Patients with malignant disease localised
to the organ of origin of the primary tumour did have reduced natural
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cytotoxicity when compared to benign controls however this difference
was not statistically significant with the number of patients studied.
Those patients with disseminated malignant disease with evidence of
distant tumour metastases did have profoundly reduced natural
cytotoxicity when compared to the benign controls. This would suggest
that depression of NK lymphocyte activity in patients with malignant
gastrointestinal tumours is directly related to tumour burden.
The effect of passage of blood through the tumour circulation on natural
cytotoxicity showed no statistically significant depression of cytotoxicity
in the tumour draining venous blood in the majority of patients. It
may be that the speed of transit of a natural killer lymphocyte in whole
blood through the tumour circulation from the arterial to venous side
is too rapid (in the order of several seconds only) for depressant
factors produced by the tumour to have sufficient time to act on the NK
lymphocytes. Further evidence, however, that malignant tumours of the
gastrointestinal tract directly influence natural killer cell activity
was found after incubation for 1 hour of lymphocytes from normal control
subjects with plasma from cancer patients. Plasma from the peripheral
venous blood of the cancer patients had a moderate depressant effect on
cytotoxicity to K562 target cells and plasma from the tumour draining venous
blood caused profound depression of cytotoxicity strongly suggesting the
production of a depressant factor which could inhibit inate natural
cytotoxicity of the host to metastatic tumour formation. This factor
appeared to be heat stable and not a result of immune complex formation
in the tumour. This depressant factor was not produced by the stomach
or colon of patients with benign disease giving further support for the
production of a tumour or tumour associated factor, present in high
concentration in the tumour draining venous blood and possibly also the
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venous blood draining adjacent macroscopically normal stomach or colon,
which depress natural cytotoxicity of lymphocytes to tumour targer cells.
Investigation of the vi/hite blood cell populations across the tumour
have suggested that some tumours were sequestering white blood veils,
mainly polymorphonuclear leucocytes however there was no convincing
evidence of sequestration of Leu 7 NK lymphocytes to account for the




Experimental results relating to the behaviour of lymphocytes during
anaesthesia and surgery.
5.1 Introduction.
5.2 The cytotoxicity in vitro against K562 target cells of natural
killer lymphocytes from patients with benign and malignant
disease during surgery under infusion anaesthesia.
5.3 The cytotoxicity in vitro against K562 target cells of natural
killer lymphocytes from patients with benign and malignant disease
during surgery under inhalational anaesthesia.
5.4 Natural cytotoxicity against K562 targets in patients with
disseminated malignant disease during surgery. Comparison with
patients with local malignant disease.
5.5 Cytotoxicity against K562 targets of peripheral blood taken before
anaesthesia, during anaesthesia alone and during surgery in patients
with benign and malignant disease.
5.6 Total white blood cell counts, polymorphonuclear leucocyte counts
and total lymphocyte counts before and during surgery in patients
with benign disease.
5.7 Total white blood cell counts, polymorphonuclear leucocyte counts
and total lymphocyte counts before and during surgery in patients
with cancer.
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5.8 Analysis of lymphocyte subpopulations in cancer patients before
and during surgery using monoclonal antibody (Leu 7).
5.9 The percentage of Leu 7 positive cells in the peripheral
venous blood pre anaesthesia, pre surgery and during surgery
in cancer patients.
5.10 Cytotoxicity of whole blood towards K562 target cells, during
surgery and 48 hours following surgery in patients with benign
abdominal disease.
5.11 Cytotoxicity of whole blood towards K562 target cells, during
surgery and 48 hours following surgery in patients with malignant
abdominal disease.
5.12 Plasma interferon levels before and during surgery in patients
with benign disease and cancer demonstrating elevated natural
cytotoxicity during surgery.
5.13 The effect of exogenous interferon in vitro on natural
cytotoxicity towards K562 targets of lymphocytes taken during




The main treatment modality of patients with potentially curable
gastrointestinal cancer is surgical resection of the tumour under
general anaesthesia . Natural killer (NK) lymphocytes have been shown,
in experimental animals, to actively destroy tumour cells injected
intravenously (Riccardi et al 1979) and this evidence infers a role
for the NK lymphocyte in defence against tumour metastases. The
experiments described in this chapter were designed to study the
cytotoxicity of natural killer cells to tumour target cells in vitro
from patients with benign disease and cancer to determine whether
general anaesthesia or surgical operation adversely affects the
behaviour of this limb of the immune defence system, which may play
a critical role in preventing tumour spread via the blood and hence
prevent the development of metastases.
5.2 The cytotoxicity in vitro against K562 target cells of natural
killer lymphocytes from patients with benign and malignant
disease during surgery under infusion anaesthesia.
In 11 patients with benign upper abdominal disease and 6 patients with
malignant disease confined to either the stomach or colon, definitive
surgical operations were performed under intravenous infusion anaesthesia
using Etomidate and Fentanyl (Jones et al 1983). This anaesthetic
technique is currently under evaluation and therefore strict criteria
for patient selection were exercised by the anaesthetists so that no
patient over 65 years of age received this type of anaesthesia. Five
millitres of venous blood was taken by peripheral venepuncture into
heparinized tubes before induction of anaesthesia and again one hour
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after induction of anaesthesia and during the definitive surgical
procedure. These blood samples were used in a whole blood cytotoxicity
assay against K562 target cells and the results expressed as percentage
cytotoxicity (Figure 1).
Of the 11 patients u/ith benign disease, 8 showed elevation of percentage
cytotoxicity of whole blood during the surgical procedure compared to
blood taken before anaesthesia, one patient showed no change and in
2 patients, percentage cytotoxicity was depressed during the surgical
procedure. The mean percentage cytotoxicity ± SEN rose from 18.9 ± 4.1
before anaesthesia to 23.7 ± 3.1 during surgery, on statistical analysis
of the grouped data the difference was not significant (by paired "t"
test).
The 6 patients with malignant disease who had their definitive surgical
procedure under infusion anaesthesia all showed a marked rise in percentage
cytotoxicity during surgery. The mean percentage cytotoxicity ± SEfl rose
from 13.9 ± 1.5 before anaesthesia to 28.4 ± 3.2 during anaesthesia
and was shown to be highly significant by the paired "t" test (p<0.001).
5.3 The cytotoxicity in vitro against K562 target cells of natural
killer lymphocytes from patients with benign and malignant
disease during surgery under inhalation anaesthesia.
Nine patients with benign upper abdominal disease and 12 patients with
malignant disease confined to the stomach or colon had definitive
surgical operations performed under conventional inhalational anaesthesia,
using nitrous oxide, halothane and oxygen. Five millilitres of blood
was taken from a peripheral vein before the induction of anaesthesia and
during the surgical procedure. These blood samples were used in a whole
111.
, FIGURE 1
PERCENTAGE CYTOTOXICITY TO K562 TARGETS OF PATIENTS
WITH BENIGN AND MALIGNANT DISEASE DURING SURGERY
UNDER INFUSION ANAESTHESIA



























± SEM ±1.5 p < 0.001 ±3.2
4 hr. chromium release assay of whole blood against K562 target.
^/2 dilution with RPMI.
Statistical analysis by the paired "t" test.
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blood cytotoxicity assay against K562 target cells and the results
expressed as percentage cytotoxicity (Figure 2).
Six of the 9 patients with benign abdominal disease showed elevated
levels of percentage cytotoxicity during surgery. One of the remaining
3 patients showed depression of cytotoxicity during surgery and 2 patients
showed no change in cytotoxicity during surgery. The rise in mean ± SEM
cytotoxicity for the benign patients from 11.9 ±2 before induction of
anaestehsia to 21.8 ± 4.5 during surgery was not found to be significant
by the paired "t" test.
Twelve patients with malignant tumours confined to the stomach or colon,
had definitive surgical procedures under conventional inhalational
anaesthesia. Eight of the 12 patents displayed elevated levels of
percentage cytotoxicity to K562 target cells during surgery and this was
reflected in a rise in the mean ± SEM cytotoxicity for the group from
9.8 ± 2.0 to 12.7 ± 1.85 This was statistically significant when
analysed by the paired "t" test (p<0.01).
5.4 Natural cytotoxicity against K562 targets, in patients with
disseminated disease during surgery. Comparison with patients
with local malignant disease.
The 8 patients with disseminated malignant disease were considered
separately since it was known that this group of patients had significant
reduction of natural killer lymphocyte activity compared to patients with
malignant disease confined either to the stomach or colon. (See chapter 4,.
Five of the 8 patients with disseminated malignancy had elevation of
cytotoxicity during the palliative surgical procedure with 2 patients
showing depression and the remaining patient showing no change of
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FIGURE 2
PERCENTAGE CYTOTOXICITY TO K562 TARGETS OF PATIENTS
WITH BENIGN AND MALIGNANT DISEASE DURING SURGERY
UNDER INHAL AT ION AL ANAESTHESIA
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± SEM ± 2.0 ±1.85
4 hr. chromium reiease assay for whole blood against Kb62 targets.
^/2 dilution with RPMl.
Statistical analysis by the paired "t" test.
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cytotoxicity during surgery. Seven of these patients received
conventional inhalational anaesthesia during surgery and one patient
had surgery performed under infusion anaesthesia with Etomidate and
Fentanyl. The mean ± SEM rise in percentage cytotoxicity from the
pre anaesthetic level of 5.8 ± 1.5 to 8.3 ± 2.3 was not significant
by the paired "t" test.
In figure 3b, the mean cytotoxicity of all of the patients with local
malignant disease receiving both infusion and inhalational anaesthesia
before and during the surgical procedure is shown, compared to the
mean cytotoxicity of patients with disseminated malignant disease before
and during surgery. The mean cytotoxicity of the patients with
disseminated malignancy taken before induction of anaesthesia, and also
during surgery is significantly lower (p<0.01) than the mean cytotoxicity
of the patients with localised tumours with blood samples taken before
and during surgery. The magnitude of the rise in mean cytotoxicity of
the patients with localised tumours is also greater during surgery than
the patients with disseminated disease, which suggests that the NK
lymphocytes from patients with a large tumour burden with widespread
metastatic disease may be less responsive to factors operating during the
surgical procedure under general anaesthesia which tend to enhance
nautral killer lymphocyte activity.
5.5 Cytotoxicity, against K562 targets, of peripheral blood taken before
anaesthesia, during anaesthesia alone and during surgery in patients
with benign and malignant disease.
Previous experiments had demonstrated elevated levels of cytotoxicity to
K562 target ceils during the surgical procedure under general anaesthesia
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FIGURE 3
PERCENTAGE CYTOTOXICITY AGAINST K562 TARGETS IN PATIENTS WITH DISSEMINATED
MALIGNANT DISEASE DURING SURGERY. COMPARISON WITH PATIENTS WITH LOCAL
MALIGNANT DISEASE
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-*•1 7.9 ± 5.2
p <0.01
(disseminated) 5.8±1.5*- -► 8.3±2.3
NS
p < 0.01
Comparing means pre anaesthetic and means during surgery by student's "t" test.
The rise in mean cytotoxicity during surgery for patients with local malignant disease is significant (p < 0.01) by
the paired "t" test
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(infusion and inhalation), therefore further experiments were undertaken
to "dissect" the nature of this response into events before induction
of anaesthesia, during anaesthesia alone (prior to surgery) and during
the surgical procedure under anaesthetic, five ml of peripheral venous
blood vi/as taken from 9 patients with benign disease and 17 patients
with localised gastrointestinal cancer before induction of anaesthesia,
10 minutes after induction of anaesthesia and before the skin incision,
and again 1 hour after induction of anaesthesia during the surgical
operation. These samples were used in a 4 hour cytotoxicity assay against
K562 target cells. The results (expressed as mean percentage cytotoxicity
± SEM) are shown in Figure 4.
Considering the 9 patients with benign abdominal disease, there was a
slight fall in mean ± SEM percentage cytotoxicity with induction of
anaesthesia from 13.1 ± 3.25 to 11.7 ± 2.35; this difference was not
statistically significant. The mean ± SEM percentage cytotoxicity rose
to 17.4 ± 2.6 during the surgical procedure however,' due to the small
number of patients studied this rise was not significant.
In the 17 patients studied with cancer of the stomach and large bowel,
there was a small but statistically insignificant rise in mean ± SEM
percentage cytotoxicity after the induction of anaesthesia (8.5 ± 1.2 to
9 ± 1.6) but a highly significant rise (p<0.005)during surgery to
14.7 ± 2.4 per cent.
These results show that natural cytotoxicity mediated by host lymphocytes
is enhanced during surgery under general anaesthesia but not anaesthesia
alone in patients with benign abdominal disease and cancer of the stomach
and large bowel. This enhancement of natural cytotoxicity is therefore
likely to be related to the surgical procedure itself.
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FIGURE 4
PERCENTAGE CYTOTOXICITY TO K562 TARGETS. BEFORE ANAESTHESIA.
DURING ANAESTHESIA AND DURING SURGERY IN PATIENTS WITH BENIGN
AND MALIGNANT DISEASE. (1/2 DILUTION OF WHOLE BLOOD)
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^ p < 0.005
4 hr. chromium release cytotoxicity assay for whole blood against K562 targets.
V2 dilution with RPMI.
Statistical analysis by paired "t" test.
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5.6 Total white blood cell counts, polymorphonuclear leucocyte counts
and total lymphocyte counts before and during surgery in patients
with benign disease.
Natural killer lymphocyte activity, as determined by percentage cytotoxicity
towards K562 targets, appeared to be enhanced during surgery in patients
with benign disease although the mean rise in cytotoxicity just failed
to reach statistical significance at the 5% level. A study was undertaken
to determine whether the rise in natural cytotoxicity seen during surgical
operation was related to an increase in the total white blood cell count
of peripheral venous blood taken before and during surgery.
In 9 patients with benign abdominal disease, total white blood cell counts
were determined before and during surgery. The results (Fig.5a) showed
some individual patient variation with 4 patients showing elevation of
total white blood cell count during surgery, 2 showed depression and the
remaining 3 patients had no appreciable change in total white cell numbers
during surgery. The mean ± SEM total white blood cell count rose from
6.0 ± 0.79 X 10^ cells/L before surgery to 6.9 ± 0.7 X 10^ cells/L during
surgery however this rise was not statistically significant.
Polymorphonuclear leucocyte counts (Fig. 5b) were performed before and
during surgery, with wide patient variation, but no significant difference
in the mean ± SEM polymorphonuclear leucocyte count before surgery at
3.1 ± 0.83 X 10^ cells/L to that during surgery at 3.1 ± 0.48 X 10^ cells/L.
In these patients, however, there was a rise in the mean ± SEM total
lymphocyte count (Fig.5c) as determined by morphological studies from
2.5 ± 0.32 X 10^ cells/L before surgery to 3.5 ± 0.59 X 10^ cells/L
during surgery. This rise was statistically significant (<0.02) by the
FIGURE6
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paired "t" test and may account, in part, for the enhanced natural
cytotoxicity of blood lymphocytes taken during surgery towards K562
targets.
5.7 Total white blood cell counts, polymorphonuclear leucocyte counts
and total lymphocyte counts before and during surgery in patients
with cancer.
Studies described previously had shown that in patients with localised
%
malignant disease of the stomach and colon, natural cytotoxicity of
lymphocytes towards K562 target cells was enhanced during surgery with
general anaesthesia provided either by the inhalational or intravenous
route. Total white blood cell counts were performed on 12 patients with
malignant disease before and during surgery to determine whether the
enhancement of cytotoxicity in these patients was related to an increase
in total white blood cell numbers.
The mean ± SEM total white blood cell count (Fig.6a) rose from 5.1 ± 0.6
9 9
X 10 cells/L before surgery to 8.9 ± 1.5 X 10 cells/L during surgery;
this rise was statistically significant (<0.02). four of the 12 patients
studied showed a marked increase in total white blood count during
surgery which in 2 of these patients resulted in a threefold increase
in total white blood cell numbers during surgery. In these 2 patients,
the rise in total white blood cells was due to an increase in polymorpho¬
nuclear leucocyte numbers (See Fig.6b) however the difference between
the mean ± SEM polymorphonuclear leucocyte counts before surgery
(3.27 ± 0.44 X 10^ cells/L) and during surgery (5.4 ± 1.24 X 10^ cells/L)
was not statistically significant.
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Five of the 12 cancer patients studied showed a slight rise in total
lymphocyte count during surgery (Fig.6c) however the difference between
the mean ± SEM total lymphocyte count before surgery for all 12
patients, at 3.1 ± 0.66 X 10 cells/L, and the total lymphocyte count
Q
during surgery, at 3.4 ± 0.61 X 10 cells/L, was not statistically
signficant. These results suggest that in the cancer patients studied,
the rise in total white blood cell count seen during surgery is accounted
for by rises in both polymorphonuclear leucocyte numbers and total
lymphocyte numbers during surgery, neither of which was of statistical
significance when considered separately.
3.8 Analysis of lymphocyte subpopulations in cancer patients before
and during surgery using monoclonal antibody (Leu 7).
The monoclonal antibody (Leu 7) is relatively specific for the natural
killer lymphocytes (Abo et al 1980) although it does have a slight
cross reactivity with the suppressor lymphocyte population; it was
therefore of interest to determine any correlation between the enhanced
natural cytotoxic response observed in certain patients and the presence
of NK lymphocytes assessed by staining with monoclonal antibody. (Leu 7
monoclonal antibody).
In 11 patients with histologically proven cancer confined to the stomach
or large bowel, peripheral venous blood was taken before anaesthesia, and
again one hour after induction of anaesthesia during the surgical
operation. Estimation of whole blood cytotoxicity to K562 targets was
performed using a 4 hour cytotoxicity assay. Peripheral blood lymphocytes
were separated from the pre anaesthetic and during surgery blogd samples
and stained with the monoclonal antibody Leu 7 as described in materials
and methods. The number (%) of cells staining were determined by ultra¬
violet microscopy.
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The results of monoclonal antibody staining (as determined by indirect
membrane immunofluoresence) are expressed as the percentage of Leu 7
positive cells, together with the cytotoxic activity towards K562
targets during surgery are presented in Table I . Nine of the 11
patients studied showed elevated levels of cytotoxicity to tumour target
cells during surgery, 8 of these patients demonstrated a rise in the
percentage of Leu 7 positive or NK lymphocytes during surgery and only
one patient (JH) with elevated levels of cytotoxicity during surgery
showed a slight fall in the percentage of Leu 7 positive cells.
Examining the results from this group of cancer patients as a whole, 9
of the 11 patients showed elevation of natural cytotoxicity during
surgery which is likely to be related to the mean ± SEN rise in percentage
Leu 7 positive cells (NK) during surgery from 18.4 ± 2.11% to 27.4 ±
2.51%, which represents a significant (p<0.05) rise in Leu 7 positive
cells by the paired "t" test.
In the one patient (AHj who had depressed natural'cytotoxicity to K562
targets during surgery, the percentage of Leu 7 positive cells was also
reduced and in a further patient (HW) although the percentage of Leu 7
positive cells was reduced during surgery, there was no demonstrable
effect on percentage cytotoxicity during surgery.
These results suggest that the overall enhancement of natural cytotoxicity
to tumour target cells seen during surgery is related to an absolute
increase in cell numbers expressing the antigen determinant reactive




PERCENTAGE OF LEU 7 POSITIVE STAINING CELLS BEFORE
ANAESTHESIA AND DURING SURGERY IN PATIENTS WITH
CANCER COMPARED TO THE EFFECT ON CYTOTOXICITY TO
K562 TARGETS
% Leu 7 +ve cells
Cytotoxicity
Patient Site of tumour PA DS during surgery
NW Colon 12.4 15.8 Elevated
AP Colon 37.0 33.9 Depressed
FW Colon 18.0 52.0 Elevated
EM Rectum 17.0 22.0 Elevated
MS Colon 7.0 10.0 Elevated
WW Colon 18.0 41.0 Elevated
JH Rectum 23.0 21.0 Elevated
AH Colon 8.3 29.0 Elevated
AC Stomach 11.0 27.0 Elevated
BR Stomach 20.0 27.0 Elevated
HW Stomach 31.0 23.0 No change
Mean 18.4 p <0.05 27.4
< >
- SEM ±2.77 ±3.51
PA = pre anaesthetic DS = during surgery
Leu 7 positive staining cells determined by indirect membrane ammino fluorescence.
Cytotoxicity of peripheral blood to K562 targets as determined by the 4 hr. chromium
release assay.
Statistical analysis by the paired "X" test.
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5.9 The percentage of Leu 7 positive cells in the peripheral venous
blood pre anaesthesia, pre surgery and during surgery in cancer
patients.
A previous study had shown that the rise in natural cytotoxicity to
K562 target cells in patients u/ith cancer did not occur during anaesthesia
alone but was evident during surgery undertaken with general anaesthesia,
suggesting that the enhancement in natural cytotoxicity is related to
the surgical procedure itself.
In this study, whole blood was taken by peripheral venepuncture from 12
patients with localised cancer before induction of anaesthesia, during
anaesthesia alone and during surgery. Lymphocytes were separated from
the whole blood samples on lymphocyte separation medium and stained with
Leu 7 monoclonal antibody in an indirect fluorescent assay prior to
examination by ultraviolet microscopy. In figure 7, it can be seen that
there is no significant rise between the mean ± SEM percentage of Leu 7
positive cells pre anaesthetic (20.6 ± 2.9?o) to the mean ± SEM percentage
during anaesthesia but before surgery (22.8 ± 2.67%). There was
however,a statistically significant rise (p<0.02) in the mean ± SEM
percentage of Leu 7 positive cells during surgery (28.7 ± 3.4).
The fact that the rise in percentage Leu 7 positive cells occurs only
during surgery under general anaesthesia, but not during anaesthesia alone
closely reflects the enhancement of natural cytotoxicity seen in patients
with cancer during the surgical procedure under anaesthesia but not
under anaesthesia alone. This strongly suggests that enhancement is at
least, in part, due to an absolute increase of lymphocytes expressing the




PERCENTAGE OF LEU 7 CELLS BEFORE ANAESTHESIA, DURING ANAESTHESIA ALONE

























*p < 0.02 by paired "t" test
Leu 7 positive cells determined by indirect membrane immuno fluorescence
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5.10 Cytotoxicity of whole blood, towards K562 target cells, during
surgery and 48 hours following surgery in patients with benign
abdominal disease.
In 5 patients with benign abdominal disease undergoing surgery,
peripheral venous blood was taken into heparinised tubes before the
induction of anaesthesia, during the surgical operation and again
48 hours following surgery. This blood was used in a 4 hour whole
blood assay against K562 target cells and the results expressed as
percentage cytotoxicity (Table II). Four of the 5 patients showed
considerable elevation of percentage cytotoxicity during surgery which
was reflected in a significant rise (p<0.02) in mean cytotoxicity from
14.3 ± 3.2 (before induction of anaesthesia) to 30.8 ± 4.2 (during the
surgical procedure). Most patients then demonstrated a fall in
percentage cytotoxicity 48 hours after surgery with a resultant fall in
mean cytotoxicity ± SFM to 17.3 ± 3.1. This activity was not
significantly different from the observed pre anaesthetic cytotoxicity
for the group (14.3 ± 3.2). These results suggest that natural cyto¬
toxicity of whole blood is elevated during surgery but falls to pre
surgery levels within 48 hours of the surgical procedure.
5.11 Cytotoxicity of whole blood, towards K562 target cells, during
surgery and 48 hours following surgery in patients with
malignant abdominal disease.
In 9 patients with histologically proven malignant disease confined to
the stomach or large bowel, peripheral venous blood was taken before the
induction of anaesthesia, during the surgical procedure and 48 hours




PERCENTAGE CYTOTOXICITY OF WHOLE BLOOD (1/2 DILUTION)
FROM PATIENTS WITH BENIGN DISEASE DURING SURGERY AND
2 DAYS FOLLOWING SURGERY
Patient Diagnosis Pre-anaes. During surgery 2 days after surgery
KH Close colostomy 22.5 22.7 25.0
EB Gallstones 11.4 27.2 17.9
WW Duodenal ulcer 19.2 33.8 16.7
DS Close colostomy 4.0 13.5 20.7
GB Duodenal ulcer 14.3 47.4 6.2
Mean cytotoxicity 14.3 30.8 17.3
- S.E.M. ± 3.2 ±4.2 ±3.12
P value p < 0.02
<
NS
4 hr. chromium release assay for whole blood against K562 targets.
Vz dilution with R.P.M.I.
Statistical analysis by the paired "X" test.
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TABLE HI
PERCENTAGE CYTOTOXICITY OF WHOLE BLOOD (1/2 DILUTION)
FROM PATIENTS WITH CANCER DURING SURGERY AND 2 DAYS
FOLLOWING SURGERY
Patient Diagnosis Pre-anaes. During surgery 2 days after surgery
DG Ca. colon 11.7 21.9 11.5
JB Ca. colon 20.8 15.5 17.1
WW Ca. colon 6.8 18.9 14.1
JC Ca. colon 26.3 23.4 22.1
RR Ca. colon 5.8 4.0 5.1
FW Ca. colon 11.9 19.8 18.7
NF Ca. colon 16.5 23.7 16.9
DP Ca. colon 17.5 31.1 15.7
PW Lymphoma stomach 9.5 30.8 32.7
Mean cytotoxicity 14.0 21.0 17.1







4 hr. chromium release assay for whole blood against K562 targets.
>2 dilution with R.P.M.I.
Statistical analysis by the paired "t" test.
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against chromium -labelled K562 target cells, and the results
expressed as percentage cytotoxicity (Table III). Six of the 9 patients
showed elevation of percentage cytotoxicity during surgery with a
statistically significant rise (p<0.05) in mean cytotoxicity ± SEM
from 14.0 ± 2.25 (pre anaesthesia) to 21.0 ± 2.73 (during the surgical
procedure). In 6 patients there was a fall in percentage cytotoxicity
48 hours after surgery with no statistically significant difference
between the mean cytotoxicity ± SEM in blood taken pre anaesthetic
(14.0 ± 2.25) and 48 hours post surgery (17.1 ± 2.52).
This data would suggest that in patients with malignant disease of the
stomach and large bowel, natural cytotoxicity to K562 tumour target
cells is elevated during the surgical operation and falls towards the
pre anaesthetic level in most patients within 48 hours of surgery.
5.12 Plasma interferon levels before and during surgery in patients
with benign disease and cancer, demonstrating elevated natural
cytotoxicity during surgery.
In 9 patients (3 benign disease, 6 malignant disease) who demonstrated
elevated levels of natural cytotoxicity during surgery, plasma was
available from the pre surgery and during surgery blood samples, which had
been used in the whole blood assay to determine natural cytotoxicity, for the
measurement of interferon by the inhibition of virus cytopathic
technique described in materials and methods. Interferon is a potent
stimulator of antitumour natural killer lymphocyte cytotoxicity
(Herberman et al 1979, Karen et al 1981, Stewart et al 1982) and this
experiment was conducted to determine whether the rapid production
of interferon (IFN) during surgery was related to, and possibly the
131.
mechanism of, elevated natural killer lymphocyte activity which occurred
during the surgical operation. It is known that IFN can recruite
precursor cells into mature NK lymphocytes as well as enhance the
recycling capacity of individual NK cells (Ullberg et al 1981).
The rise in percentage cytotoxicity of the 3 benign and 6 malignant
patients during the surgical procedure was highly significant (p<0.001):
from 12.7 ± 1.58 to 26.6 ± 3.6 (Table IV). Further tests showed that
the rise in percentage cytotoxicity in individual patients during the
surgical procedure was not associated with a rise in plasma interferon
levels during surgery which in all cases was measured at less than 8.5IU/ml.
In our laboratory, enhancement of natural cytotoxicity of whole blood
against K562 targets using the amount of blood used in these experiments
(100 yL) is consistently found with the addition of exogenous interferon
at a concentration of 100 IU/ml. The results in this experiment show
that interferon is not produced during the surgical operation and that
the levels of interferon detected in the plasma samples were probably
too low to account for enhancement of cytotoxicity of the natural killer
lymphocytes present in the whole blood samples. It would appear that
the enhanced cytotoxic response to K562 targets seen during the surgical
procedure in both patients with benign and malignant abdominal disease,
is not therefore due to the rapid production of interferon during
surgery.
5.13 The effect of exogenous interferon in vitro on natural cytotoxicity
towards K562 targets of lymphocytes taken during surgery in patients
with benign disease and cancer.
Previous experiments described in this chapter showed that in many




PLASMA INTERFERON LEVELS BEFORE AND DURING SURGERY
IN PATIENTS WITH BENIGN DISEASE AND CANCER
Percentage cytotoxicity Interferon
Patient to K562 lU/ml
PA DS PA DS
WW (duodenal ulcer) 4.1 33.8 <8.5 <8.5
PB (gallstones) 18.0 45.0 <8.5 <8.5
EB (gallstones) 11.4 27.2 <8.5 <8.5
FW (ca. colon) 11.9 19.8 <8.5 < 8.5
EM (ca. rectum) 8.3 14.2 <8.5 < 8.5
*WD (ca. colon) 13.3 18.2 <8.5 < 8.5
BR (ca. stomach) 19.1 40.4 <8.5 <8.5
JH (ca. rectum) 11.8 17.5 <8.5 <8.5
NF (ca. colon) 16.5 23.7 <8.5 <8.5
Mean 12.7 p < 0.001 26.6
-S.E.M. ±1.58 ±3.6
^Disseminated disease.
PA = pre anaesthetic DS = during surgery
4 hr. chromium release cytotoxicity assay of whole blood against K562 targets
Vz dilution with RPMI
Interferon measured by inhibition of virus cytopathic effect method
Statistical analysis by paired "X" test
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tract, the capacity of natural killer lymphocytes to lyse K562 target
cells was enhanced during the surgical procedure. This effect was
related to an observed increase in the percentage of Leu 7 positive
cells (i.e. mature NK lymphocytes) during surgery. It was of interest
therefore to determine whether natural killer lymphocyte ability to kill
tumour target cells could be enhanced yet further during the surgical
procedure. This could prove beneficial to patients undergoing resection
of a malignant tumour when it is known that tumour cells are liberated
into the circulating blood, particularly with manipulation of the tumour,
with respect to increased tumour cell lysis and prevention of metastatic
spread.
In 9 patients, 5 with benign abdominal disease and 4 with gastrointestinal
cancer, peripheral venous blood was taken one hour after induction of
anaesthesia and start of surgery. Lymphocytes were separated from the
whole blood samples as described previously using lymphocyte separation
medium, and suspended at a concentration of 1 X 10^ cells per ml.
Lymphocytes were incubated with or without the addition of 100 IU of
exogenous human leucocyte a interferon at 37°C in a 5% CO^ atmosphere
and subsequently assayed for cytotoxicity against K562 targets in a
4 hour chromium release assay.
The results for the 5 patients with benign disease are shown in Table V.
Three patients displayed a significant enhancement (p<0.005 - p<0.01 by
paired "t" test) of cytotoxicity to K562 tumour targets after incubation
of PBL's taken during surgery with interferon. In 2 patients (OS, FI)
although there was a rise in cytotoxicity after incubation of PBL's with
interferon, this is not statistically significant. Both of these
patients PBL's had very high initial levels of cytotoxicity and it may
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TABLE V
THE in vitro EFFECT OF HUMAN LEUCOCYTE a INTERFERON
ON PERCENTAGE CYTOTOXICITY OF PBL'S TAKEN FROM
BENIGN PATIENTS DURING SURGERY
Patient Diagnosis % Cytotoxicity - S.E.M. % Cytotoxicity - S.E.M. p value
— Inf. + Inf.
Bl Benign weight
loss
38.0 + 0.5 60.2 + 4.2 <0.01
MS Gallstones 21.7 + 0.8 40.0 + 2.1 <0.05
cs Gallstones 66.2 + 0.5 75.9 + 10.0 NS
est Gallstones 5.5 + 1.1 12.2 + 1.6 <0.05
Fl Gallstones 76.6 + 4.6 82.4 + 1.2 NS
4 hr. chromium release assay for PBL's against K562 targets.
Effector : target ratio 25 : 1
Inf. = Interferon




THE in vitro EFFECT OF HUMAN LEUCOCYTE d INTERFERON ON
PERCENTAGE CYTOTOXICITY OF PBL'S TAKEN FROM CANCER
PATIENTS DURING SURGERY
Patient Tumour % cytotoxicity - S.E.M. % cytotoxicity - S.E.M. p value
— Inf. + Inf.
WW (Ca. colon) 66.5 ± 3.7 79.0 ± 5.0 NS
disseminated
NF (Ca. stomach) 0.9 ± 0.6 2.0 ± 1.1 NS
PH (Ca. rectum) 31.3 ± 4.1 53.0 ± 2.3 <0.02
FH advanced
(Ca stomach) 45.0 ± 3.3 70.0 ± 0.7 <0.01
4 hr. chromium release cytotoxicity assay of PBL's against K562 targets.
Effector : target ratio 25 : 1
Inf. = Interferon
Statistical analysis by paired "t" test
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be that they are incapable of further stimulation in terms of increased
binding and recycling capacity to result in a significant enhancement
of cytotoxicity.
The results for the 4 patients with malignant disease are shown in
Table VI. Two patients had tumours localised to the large bowel and
two had disseminated gastric cancer. Two patients (PR Ca rectum,
FH Ca stomach) displayed significant enhancement (31.3 ± 4.1 - 53 ± 2.3%
p<0.02, 45 ± 3.3 - 7(1 ± 0.75o p<0.01)of cytotoxicity to K562 by PBL's
taken during surgery after in vitro exposure to interferon. Patient WW
did show enhancement of cytotoxicity after exposure of PBL's to interferon
(66.5 ± 3.7 - 79 ± 5.0) but this failed to reach statistical significance
by the paired "t" test. Patient NF had widely disseminated gastric
cancer with very low levels of cytotoxicity to K562 targets during
surgery (0.9 ± 0.6?o) which did not increase significantly after overnight
exposure of PBL's to interferon which implies that NK lymphocytes from
this patient were refractory to interferon.
These experiments showed that in some patients with cancer, further
boosting of already elevated levels of natural cytotoxicity of
lymphocytes to tumour target cells can occur following exposure to human
leucocyte a interferon. This could prove of potential therapeutic
benefit to patients undergoing resection of a malignant tumour, since
enhanced NK cell activity may result in improved lysis of circulating
tumour cells and reduction in the likelihood of metasatic tumour
formation.
5.14 Discussion.
The experiments described in this chapter show that the antitumour
cytotoxic capacity of natural killer lymphocytes, present in circulating
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blood is enhanced during the surgical procedure in patients with
localised tumours of the stomach and large bowel receiving either
inhalational or intravenous anaesthetic agents. Patients with benign
disease may also show an enhanced response during surgery; however,
patients with advanced malignant disease with tumour metastases failed
as a group to show significant enhancement of natural cytotoxicity
against K562 tumour target cells during surgery.
This enhancement of natural cytotoxicity seen in patients with localised
tumours occurred during the surgical procedure under general anaesthesia
but not during anaesthesia alone, in addition the elevated levels of
cytotoxicity seen during surgery declined to the pre operative levels
within 48 hours folJowing operation in patients with benign abdominal
disease and cancer.
The mechanism of this observed enhancement of the cytotoxicity of natural
killer lymphocytes towards tumour cells was not the result of a rapid
production of interferon during surgery but appeared to be largely due
to an increase in absolute numbers of lymphocytes expressing HNK1 antigen (Leu
(Abo et al 1980), since Leu 7 monoclonal antibody staining cells were
increased in number during surgery. This resulted in an increased
number of natural killer lymphocytes present in the circulating blood
during the surgical operation, which in patients with cancer could
prove to be beneficial, possibly acting on tumour cells liberated from
the tumour, particularly during surgical manipulation, and hence
improving host defence against potential metastatic spread of the disease.
The enhancement of natural cytotoxicity during the surgical procedure in
patients with benign abdominal disease occurring in response to stress
of the surgical procedure may represent a natural phenomenon necessary
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to deal with the potential infectious agents acquired during surgery
whilst in the patients with cancer, this defence mechanism is mobilised
against liberated tumour cells (Griffith et al 1983). The rise in NK
lymphocyte numbers during the surgical procedure probably represents a
recruitment response with liberation of NK lymphocytes from precursor
cells present in the circulating bone marrow, which results in a
temporary redistribution of the NK lymphocytes capable of dealing with
the intra operative liberation of tumour cells. This then returns
to normal tissue distribution within 48 hours of surgery, resulting
in a decline in cytotoxicity to pre operative levels. The failure
of patients with metastatic malignancy, and hence large tumour burden,
to show elevated levels of natural cytotoxicity to tumour cells during
the surgical procedure is perhaps not surprising, since at this stage
the tumour may have overwhelmed the host's defence mechanisms against
both primary and secondary (metastatic) tumour formation.
The final series of experiments described here show -that natural killer
lymphocyte activity was enhanced in patients with benign disease and
some cancer patients by exposure of blood lymphocytes to exogenous
leucocyte a interferon in vitro. This points to the exciting possibility
that in patients with cancer undergoing surgical resection of the tumour,
the in vivo use of interferon could be used before surgery to boost
natural killer lymphocyte activity of the host. This may then favour
enhanced tumour cell lysis during and following the period of surgery
when large numbers of tumour cells have been liberated from the tumour.
This boosting would facilitate an enhancement of the already elevated
natural cytotoxicity occurring during surgery in patients with localised
tumours.
Such enhancement activity of the body defences may benefit host survival
by increasing the likelihood of lysis of circulating tumour cells with
139.
a potential reduction in tumour metastases seeded at the time






Natural killer (NK) lymphocytes have been described in a variety of
animal species including man (Rosenberg et al 1972; Kay and Sinkovics
1974; West et al 1977). The natural killer lymphocyte possesses the
ability to recognise and cause lysis of abnormal cells such as tumour
cells and cells infected by viruses, u/ithout the reguirements for prior
sensitisation to a specific surface antigen (Roder et al 1980). The NK
lymphocyte however, does possess a degree of specificity and can recognise
macromolecular structures on the surface membranes of susceptible cells
which may be transferrin receptor sites (Vodinelick et al 1983); a
conjugate is then formed between the NK lymphocyte and the susceptible
cell prior to cell lysis (Hiserodt et al 1982). The NK lymphocyte
then dissociates from the tumour cell and is available to bind to and
kill further tumour cells. The behaviour of NK cells towards
abnormal cells, particularly tumour cells, and the fact that they are
found in many vertebrate species (rat, hamster, mouse and man) implies
that they have a role in primary immune defence against developing
tumours (Herberman and Ortaldo 1981) since they can be active within
hours of exposure to tumour cells in vivo compared to the time course of
5 to 7 days required for the sensitised cytotoxic T lymphocyte or ADCC
to be effective towards and destroy tumour cells (Perrin et al 1977;
Zinkernagle and Doherty 1979). NK lymphocytes have also been shown to
be active against the haematogenous spread of tumour cells, causing lysis
of circulating tumour cells and preventing metastatic tumour formation in
mice (Riccardi et al 1979; Hanna and Fidler 1980), and it seems likely
that they may have a similar role in defence against secondary haematogenous
spread of tumour cells in man.
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Patients with immune deficiency syndromes have an increased incidence
of malignant disease particularly lymphocyte proliferative disorders,
compared to normal controls. Thus, patients with hypogammaglobulinaemia
have an increased incidence of leukaemia, those with Chediak Higashi
syndrome, in which there is a selective deficit of natural killer
lymphocyte activity, are prone to develop lymphoma and those patients
receiving high dose immunosuppressive therapy following organ trans¬
plantation are more likely to develop lymphoma and epithelial tumours
such as skin cancer and cancer of the cervix. These findings would
appear to indicate a basic failure of immunological surveillance as
pioneered by Burnett.
The NK lymphocyte,because of rapid recognition and subsequent lysis of
abnormal cells such as tumour or virus infected cells,has been advocated
as a primary mechanism in immune surveillance against developing tumour
formation (Greson 1980; Herberman and Ortlado 1981).
6.2. Tumour effect on NK lymphocyte activity.
Patients with established malignant disease,whether lymphoma or carcinoma,
have been shown by many workers to have depressed NK lymphocyte cytotoxicity
to tumour target cells in vitro when compared to non malignant controls
(Pross and Baines 1976; Gerson 1980; Hawrylowicz 1982).
The depressed NK lymphocyte activity in patients with malignant disease
correlates with the extent of dissemination of the disease or tumour
burden rather than the stage of the primary tumour. Patients with early
breast cancer were found to have comparable levels of NK lymphocyte
activity in the peripheral blood as controls (Eremin 1980), which is
similar to the results presented in this thesis, in that patients with
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malignant disease localised to the stomach or large bowel had NK activity
in peripheral venous blood u/ithin the range of patients with benign
abdominal disease. The reduction in NK activity of circulating
lymphocytes found in patients with disseminated malignancy strongly
suggests that the tumour itself has a direct effect on NK lymphocyte
activity of the host. These patients could have a defect in immune
defence which has allowed the tumour to develop and subsequently con¬
solidate its hold on the host by adversely affecting the host response
to the tumour, or alternatively the tumour cells are resistant to NK
lysis or cause the production of factors which suppress host natural
cytotoxicity.
As further evidence for a direct tumour effect on NK lymphocyte
activity, various workers have studied tumour infiltrating lymphocytes
(TIL's) for NK mediated cytotoxic effects to tumour target cells. Most
workers found either low or absent natural cytotoxicity of TIL's to
K362 tumour targets (Vanky and Klein 1982, Bland et al 1981, Vose and
Moore 1979) and studies in our laboratory on tumours from patients used
in this study have shown that most colorectal tumours have low, but
detectable,levels of natural cytotoxicity to K562 target cells. (Clegg
and Rees, personal communication). Studies of tumour draining lymph
nodes in patients with breast cancer (Eremin 1980) or large bowel cancer
(Vose et al 1980) have shown low or absent natural cytotoxicity of
lymphocytes in these nodes suggesting a direct tumour effect on these
cells. Low levels of natural cytotoxicity in tumour infiltrating and
nodal lymphocytes by possible modulation of NK cell activity by the
tumour may be a mechanism for continued growth and spread of malignant
tumours.
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Possible reasons for depressed natural killer cell activity from
intratumour lymphocytes are that there are low numbers of effector
cells within the tumour or that the tumour infiltrating lymphocytes
with natural killer cell activity are present but their activity is
inhibited by tumour or host ceil derived factors.
Introna et al (1982) have suggested that low intratumour NK activity
could be due to low numbers of effector cells. This is not supported
by experiments from workers in our laboratory who have shown that many
colorectal tumours have low but significant levels of NK cytotoxicity
to K562 target cells. Similarly histochemical staining using the Leu 7
monoclonal antibody which identifies NK lymphocytes have shown substantial
numbers of lymphocytes with a positive staining reaction with Leu 7 antibody
(Fig.l.) in colorectal cancers and breast cancers (Rooney 1983, personal
communication) and Leu 7 positive cells in colorectal tumour digests
account for about 8% of the tumour infiltrating host cell population.
The experiments reported in this thesis with the Leu 7 labelling of
lymphocytes in the arterial blood entering the tumour and the venous
blood draining the tumour have shown no gross change in the NK cell
(Leu 7 positive) population entering and leaving the tumour circulation.
This suggests that a steady state situation exists with respect to NK
lymphocytes in the blood passing through the tumour ciculation and the
intratumour NK lymphocytes, and that net sequestration of NK lymphocytes
in the tumour does not occur. Further evidence that low intratumour
NK lymphocyte activity is not due to low numbers of effectors comes from
Golub et al (1982) who has shown with the single cell assay that depressed
NK activity of tumour infiltrating lymphocytes is due to the presence
of suppressive factors within the tumour.
FIGURE 1.
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SECTION OF A COLONIC ADENOCARCINOMA SHOWING LEU 7 POSITIVE (NK) LYMPHOCYTES
IN THE TUMOUR SUBSTANCE.
(Histochemical staining technique combined with Leu 7 antibody makes Leu 7
positive cells appear brown - courtesy of Dr. N. Rooney,!.
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NK lymphocyte activity in established malignant tumours may be suppressed
directly by tumour products or activation of host cells such as
macrophages or lymphocytes by the tumour which then produce factors
which directly suppress NK activity.
Malignant tumours are known to produce hormones and other biologically
active products which are related to the lineage of the malignant
cell, however, some tumour products seem to be able to directly influence
the host response to the tumour with marked depression of that response.
Serum from patients with cancer inhibited the cytotoxicity of peripheral
blood T lymphocytes to tumour target cells (Nind et al 1975) and serum
from patients with advanced gastric carcinoma induced suppressor cell
activity in lymphocytes which then caused inhibition of lymphocyte
transformation (Toge et al 1983).
Edwards et al (1973) showed that a factor present in the blood directly
draining gastrointestinal tract tumours caused direct inhibition of
lymphocyte transformation, and in the present study tumour draining
plasma components were shown to depress NK cytotoxicity of PBL's from
normal indiviudals. Nair et al (1980) have demonstrated inhibition
of both NK and ADCC in mice with cancer sera and natural killer lymphocyte
cytotoxicity to K562 target cells was substantially reduced by
incubation with the supernatant from tissue culture of human hepatic
cancer cells (Keony et al 1983). The nature of the inhibitory effect
of the tumour product was postulated as blocking the receptor sites of
the NK effectors thus reducing binding to target cells. The results
presented in this thesis confirm the likely presence of a plasma
factor which is in high concentration in the blood draining malignant
tumours of the stomach and colon, which causes significant depression of
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natural killer lymphocyte activity from normal controls. This factor
is probably heat stable but further work is required to determine the
nature of this factor, its molecular weight and chemical structure and
also the cell responsible for producing the factor i.e. either the
tumour cells per se or intratumour lymphocytes or macrophages. It is
of considerable interest that Flannery has reported a heat stable, pH
resistant substance of low molecular weight produced by macrophages
which inhibit NK lymphocyte activity in mice (1983 personal communication),
and further studies should be initiated to determine whether intratumour
macrophages from human tumours release suppressor substances.
Circulating immune complexes have frequently been found in the blood of
patients with cancer (Day et al 1982, Hoffken et al 1977, Theofilopoulos
et al 1977, Bonavida and Zighelboim 1974) with high levels often relating
to poor patient prognosis. These complexes probably represent excess
tumour antigen which is complexed with host antibody. It would seem
reasonable to implicate immune complexes as a possible mechanism for NK
lymphocyte inhibition by binding to the Fc receptor present on the NK
lymphocyte. Studies by Timonen and Saksela (1977) have shown that
purified monoclonal lgM blocks NK cell activity and NK inhibition by
lgG containing complexes acts by preventing binding of effector cells
to target cells.
The results of the studies presented in this thesis show that tumour
draining venous plasma which caused significant depression of NK
lymphocyte activity from normal controls possessed very low levels of
immune complexes as detected by the Raji cell assay. Although this
assay is not infallible in detecting circulating immune complexes, it
would be expected that if this was a likely mechanism for the depression
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of NK lymphocyte activity, raised levels of immune complexes u/ould
be found in at least some of the patients included in the study; this
however was not shown.
Suppressor cells either by direct cell to cell contact or release of
suppressor substances may be responsible for depression of natural
killer lymphocyte activity in cancer patients.
Zoller et al (1982) found that cells recovered from Percoll gradient
separation and present in the Percoll fraction 1.D90 to 1.121 g/ml
were effective in the suppression of natural killer, K (killer) cell
and cytotoxic T cell function in mice with cell to cell contact
required for suppression. Eremin (1980) has found tumour associated
lymphocytes from patients with breast cancer caused inhibition of NK
lymphocyte activity and other workers (Vanky and Klein 1982) have
suggested the existence of nylon wool adherent tumour infiltrating
cells in colorectal cancer which inhibit natural killing of TIL's.
Adherent monoclonal cells (macrophages) from malignant pleural effusions
were found by Uchida and Michsche (1981) to suppress NK lymphocyte
cytotoxicity to tumour target cells in vitro. These studies suggest
that suppressor cells, either tumour associated lymphocytes or
macrophages, probably release suppressor substances which cause
inhibition of the NK lymphocyte's capacity to kill tumour cells.
Cudkowicz and Hochman (1979) reported that supernatants from cultured
suppressor cells from mouse spleens inhibited NK lymphocyte cytotoxicity
in mice, and Flannery (1983, personal communication) has reported a low
molecular weight product from mouse macrophages which inhibits NK cell
activity.
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Further studies with isolation of tumour associated lymphocyte and
macrophages by currently available techniques from human cancers will
help to identfy the cell population responsible for NK lymphocyte
depression in man. It is well established that prostaglandins which
inhibit NK cell function are produced both by tumours (Bennett et al
1977, 1982) and host mononuclear phagocytes (Doller et al 1978).
Further studies are required to identify the role of prostaglandins in
NK lymphocyte depression of the host.
6.3 The effects of anaesthesia and surgery on the immune response
with particular reference to the natural killer lymphocyte.
Metastatic spread of malignant tumours remain the major problem in the
treatment of malignant disease in man. From studies on experimental
animals, tumour cells are found in the circulation when blood vessels
of a given size (30ym) penetrate the growing tumour allowing tumour
cells either individually or in clumps to escape (Liotta et al 1976).
Circulating tumour cells are found in cancer patients which may lodge
in capillary networks and lie dormant for many years before forming
overt metastases (Fisher and Fisher 1967). These authors state that
"all tumour emboli may represent potential metastases" therefore their
presence in the circulating blood of patients with cancer must be taken
as evidence for the metastatic potential of the primary tumour. The
immune depression seen during anaesthesia and surgery which affects
both the humoral and cell mediated immune response has been implicated in
the dissemination of malignant disease following resection of the
primary tumour (Salo 1982).
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There is no generalised agreement as to whether it is the effects of
anaesthesia or the surgical procedure itself that causes depression
of in vitro immune responses. Of the inhalational anaesthetic agents,
halothane is associated with in vitro depression of lymphocyte
cytotoxicity (Cullen et al 1976) and inhibition of lymphocyte motility
(Nunn et al 1970) whilst nitrous oxide also inhibits cell mediated
cytotoxicity (Cullen et al 1976) and prolonged administration is toxic
to bone marrow (Bruce 1980), which is the source of NK cell precursors.
The surgical procedure was considered by Riddle (1967) and Park et al
(1971) to be the major cause of depression of in vitro lymphocyte
responses and studies by Berenbaum et al (1973) and Cullen and Van Belle
(1975) report that the lymphocyte depression following surgery was
directly related to the extent of surgical trauma.
In patients undergoing donor nephrectomy, for transplant purposes who
are free from malignant disease, there is a decrease in the number of
circulating T and B lymphocytes following surgery (Slade et al 1975)
which may also pertain for patients with malignant disease. Patients
with cancer have a reduced T cell response to mitogens during surgery
(Cullen and Van Belle 1975) and an attenuated response to antigen
stimulation (Cochran et al 1972). Cytotoxicity of lymphocytes to
autologous tumour cells is decreased post operatively in patien"ts with
breast cancer (Vose and Mougdil 1975), malignant melanoma (Cochran
et al 1972) and antibody dependent cytotoxicity or K cell activity is
decreased following operation in previously immuno suppressed cancer
patients (McCredie et al 1979).
There have been no published reports about NK lymphocyte activity
during anaesthesia and surgery in patients with cancer or benign disease
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apart from the author's (Griffith et al 1983a, Griffith et al 1983b,
Griffith et al 1983c) but other workers have found that natural killer
lymphocyte cytotoxicity to tumour target cells is depressed when measured
from the third post operative day in patients with breast cancer (Uchida
et al 1982). A study of patients with solid tumours also showed
depression of natural killer lymphocyte activity A to 6 weeks following
surgery (Flad et al 1983; however it must be stressed that neither of
these studies measured NK lymphocyte cytotoxicity to tumour target cells
during the surgical procedure. The results presented in this thesis show
that the capacity of natural killer lymphocytes to kill tumour target
cells (K362) is enhanced during the surgical operation in both patients
with benign abdominal conditions and tumours localised to the stomach or
large bowel, but patients with disseminated malignancy do not show such
marked enhancement. This effect occurs during the surgical procedure
under anaesthesia (with both intravenous and inhalational anaesthetic
agents) but not anaesthesia alone, and appears to be due to an increase
in cells bearing the monoclonal antibody marker for NK lymphocytes
(Leu 7) during the surgical procedure. This could be seen as a recruitment
response with the mobilisation of NK lymphocyte precursors from bone
marrow to cope with the likely events during the surgical procedure such
as liberation of tumour cells by manipulation of the tumour. This
recruitment response would ultimately lead to exhaustion of the bone
marrow-derived NK precursors which probably is reflected in the return to
pre operation levels of NK lymphocyte mediated cytotoxicity of the
patients studied within 48 hours of the surgical procedure, and to the
post surgical depression of NK cytotoxicity observed by other workers.
Surgical resection of the primary tumour under general anaesthesia offers
the best chance of cure of gastrointestinal cancer but it is known that
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malignant cells from the primary tumour are present in the circulating
blood before and during the surgical procedure (Engell 1955, Salisbury
et al 1965). These circulating tumour cells are viable and can be grown
in tissue culture (Moore et al 1958).
Manipulation of the tumour during surgery greatly increases the number
of circulating malignant cells (Griffith 1960) which coupled with a
degree of depression of host immune defences during anaesthesia and
surgery, may combine to produce a fertile "soil" for the seeding of
tumour cells to form potential metastatic tumour deposits.
There is abundant evidence from experimental animals of increased tumour
growth and dissemination of tumour with the formation of metastases
following anaesthesia and surgery. Grottfried et al (1961) described an
increase in the growth rate of implanted tumours after repeated surgical
wounding and El Rifi et al (1965) has reported an increased incidence
of pulmonary metastaes following laparotomy in rats; the formation of
metastases was counteracted by heparin which presumably prevented
implantation of malignant cells and thus allowed host defence mechanism
to destroy circulating tumour cells.
The evidence for increased dissemination of malignant disease in man
following surgical operation is sparse but anecdotal reports in the
literature have suggested rapid growth and metastatic spread of primary
tumours after resection of the tumour or incidental minor surgery.
(Gordon Taylor 1948, Lewis and Cole 1958, Jewell and Romsdahl 1965).
In the context therefore of immune suppression of conventional T and
B lymphocyte responses during surgical resection of primary malignant
tumours, it is encouraging to find that at least one potential mechanism
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for defence against intravascular dissemination of the tumour, namely
the natural killer lymphocyte, is enhanced during the surgical
procedure itself and remains enhanced for up to 48 hours post operatively.
The fact that the already enhanced cytotoxicity of human NK lymphocytes
to tumour target cells due to an increase in cell numbers in the
circulation can be further enhanced in vitro by exposure to interferon
leads to the exciting possibility of selective immunological enhancement
of NK lymphocyte activity in vivo with infusion of interferon pre-
operatively. This could lead to improved lysis of circulating tumour
cells and a possible reduction or abolition of metastases developing
following surgery. This concept should be evaluated by future research
using a controlled animal model system using a spontaneously metastasizing
tumour which parallels the behaviour of human cancers.
There are many clinical trials which have now been conducted that show
NK lymphocyte activity can be boosted in vivo with interferon given
by the intramuscular or intravenous route (Bordeau et al 1982 ;
Quesada et al 1982; Einhoru et al 1982; Lucero et al 1982). The
enhancement occurs 24 to 36 hours after exposure to interferon and
declines to pre exposure levels within 1 to 3 weeks. It is also of
interest that whilst the NK lymphocyte is very efficient at killing
cells from the K562 erythroleukaemia cell line, activity against
autologous tumour cells from the same patients may be low yet this can
be considerably improved by exposure to interferon in vivo (Mantovani
et al 1983), and similarly Rees et al (1983) have shown considerable
enhancement of NK mediated lysis of human ocular malignant melanoma
cells in vitro after exposure to exogenous interferon.
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There is therefore, a potential therapeutic application projected from
the results presented in this thesis that pre operative stimulation of
the host natural killer lymphocyte response by infusion of interferon
24 to 36 hours before surgery, could be used as a manoeuvre to increase
killing of circulating tumour cells during and for up to 4B hours
after the surgical resection of the primary tumour. This may reduce
or abolish the formation of metastases following surgery by preventing
the implantation of circulating malignant cells which have the potential
to become metastatic tumour deposits.
6.3 Proposed future research.
The natural killer lymphocyte may represent an effective defence against
the metastatic spread of a tumour which is already established in the
host and research into the possible tumour directed mechanisms for
depression of activity of these natural killer lymphocytes may yield an
increased understanding of the mechanisms of tumour•suppression of host
defences. I have already evidence of a tumour associated plasma factor
which causes suppression of NK lymphocyte activity in vitro. This may
be produced by the tumour cells or intra tumour host cells such as
macrophages or lymphocytes which have been directed by the tumour to
produce inhibitory substances. Isolation of tumour infiltrating cells
by currently available techniques could help to identify which cell
population is responsible for the depressant factor.
Another part of my current research has shown that natural killer
lymphocyte activity in cancer patients can be stimulated by biological
response modifiers such as interferon. Studies of interferon given
in vivo to patients with cancer have shown enhancement of natural killer
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cell activity 24 to 48 hours following injection. This phenomenon
could be used to advantage in patients undergoing resectional surgery
for cancer. Surgical manipulation of a tumour releases tumour cells
which are found in the circulating blood and with the generalised
immunosuppression associated with general anaesthesia and surgery, these
cells could form potential metastases. Enhancement of a defence
mechanism against tumour metastases such as the natural killer lymphocyte
system during the perioperative period when the patient is at risk of
implicating tumour cells to form potential metastases, could prove
beneficial in terms of improved patient survival. A clinical trial of
selective NK lymphocyte enhancement by agents such as interferon used
in the perioperative period in patients undergoing potentially curative
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